新規5-HT4受容体作動薬CJ-033466の消化管運動促進作用とそれに関連したセロトニン受容体サブタイプの薬理学的特徴に関する研究 by Tohru, Komada et al.
 
 
 
 
Elucidation for Gastrokinetic Effects of a Novel 5-HT4 Receptor 
Agonist, CJ-033466 and its Related Pharmacological Characterization 
of 5-HT Receptor Subtypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2007 
 
Tohru Komada 
 
Contents 
 
Abbreviations ……………………………………………………………….…….   1 
General Remarks ……………………………………………………..………..….   2 
Chapter I: Effects of 5-HT4 receptor agonists on gastric motility in dogs 
1. Introduction ………………………………………………………….   6 
2. Materials and Methods ………………………………………………   7 
3. Results ……………………………………………………………….   9 
4. Discussion ……………………………………………………………  21 
Chapter II: Effects of 5-HT4 receptor agonists on gastric emptying and gastric 
 motility in rats 
1. Introduction ………………………………………………………….  23 
2. Materials and Methods ………………………………………………  23 
3. Results ……………………………………………………………….  25 
4. Discussion …………………………………………………………...  43 
Chapter III: Pharmacological characterization of 5-HT-receptor subtypes in  
 circular muscle from the rat stomach 
1. Introduction ………………………………………………………….  45 
2. Materials and Methods ………………………………………………  45 
3. Results ……………………………………………………………….  47 
4. Discussion ………………………………………………………...…  58 
Chapter IV: Effects of 5-HT4 receptor agonists on contractile responses of  
 circular muscle from the rat stomach 
1. Introduction ………………………………………………………….  63 
2. Materials and Methods ………………………………………………  63 
3. Results ……………………………………………………………….  64 
4. Discussion …………………………………………………………...  78 
Chapter V: Effects of CJ-033466 on ACh release from human gastric antral tissues 
1. Introduction ………………………………………………………….  80 
2. Materials and Methods ………………………………………………  80 
3. Results ……………………………………………………………….  82 
4. Discussion …………………………………………………………...  87 
Concluding Remarks ……………………………………………………………...  88 
Acknowledgements ………………………………………………….……………  89 
References …………..…………………………………………………………….  90 
List of publications ………………………….…………………………………….. 100 
Referees …………………………………………………………………………… 101 
Abbreviations 
 
ACh  : acetylcholine 
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General Remarks 
 
  Serotonin (5-hydroxytryptamine, 5-HT) is an endogenous monoamine which has a 
wide range of physiological actions. Originally, Erspamer et al. (1) discovered a smooth 
muscle contracting substance “enteramine”, named because large amounts of it were 
stored in enterochromaffin cells of the gastrointestinal tract. Independently, Rapport et 
al. (2) identified the serum vasoconstrictor factor releasing from platelets during 
clotting of blood as “serotonin”. In 1952, enteramine was found to be identical to the 
vasoconstrictor substance known as serotonin (3). 
  The gastrointestinal tract is the main source of serotonin in the body (4). More than 
90% of serotonin in the body exists in the enterochromaffin cells of the gut mucosa. It is 
now recognized that 5-HT is also contained in the enteric nervous systems of the 
gastrointestinal tract (5). Serotonin works as a neurotransmitter and a paracrine 
signaling molecule and exerts a variety of effects on intrinsic enteric neurons, extrinsic 
afferent neurons, enterocytes and smooth muscle cells. They express multiple 5-HT 
receptor types and subtypes regulating gastrointestinal motility (6), secretion (7) and 
perception (8).  
  5-HT receptor subtypes have been classified into seven main types as 5-HT1, 5-HT2, 
5-HT3, 5-HT4, 5-ht5, 5-HT6 and 5-HT7. Furthermore, 5-HT1, 5-HT2 and 5-ht5 receptors 
have been subdivided into 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 
5-HT2C, 5-ht5A and 5-ht5B (9-11). Recently, 5-HT1E, 5-HT1F, 5-ht5, 5-HT6 and 5-HT7 
receptors subtypes have been characterized using molecular cloning techniques. 
Therefore, these receptors have not been extensively characterized pharmacologically, 
except for the 5-HT7 receptor. With the exception of the 5-HT3 receptor, which is a 
ligand-gated ion channel, 5-HT receptors belong to the G-protein-coupled receptor 
superfamily. It is generally accepted that the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 
5-HT3, 5-HT4 and 5-HT7 receptor subtypes are known to affect the gut function (12, 13). 
5-HT4 receptors couple to Gs protein and promote cAMP formation. 
5-HT is thought to be involved in the pathophysiology of several clinical entities, 
including functional gut disorders such as irritable bowel syndrome (IBS), functional 
dyspepsia, chronic constipation, carcinoid diarrhea, and chemotherapy induced emesis 
(14-17). The discovery of selective 5-HT receptor agonists and antagonists brought up 
intense interest of its application on gastrointestinal pharmacotherapy. 5-HT3 receptor 
antagonists demonstrate the potential therapeutic role for diarrhea-predominant IBS, 
carcinoid diarrhea, and chemotherapy induced emesis (18-20). 5-HT4 receptor agonists 
demonstrate the potential therapeutic role for constipation-predominant IBS (c-IBS) and 
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chronic constipation (21). 5-HT1 receptor agonists, sumatriptan (5-HT1B/1D receptor 
agonist) and buspiron (5-HT1A receptor agonist) enhanced gastric accommodation, 
indicating the therapeutic role for functional dyspepsia (22, 23).  
Furthermore, the pathophysiology of gastroesophageal reflux disease (GERD) is 
closely related to gastric dysmotiltiy. Transient lower esophageal sphincter relaxation 
(TLESR) is the most important mechanism of reflux in GERD. The induction of 
TLESRs in patients with GERD is primarily related to stimulation of mechanoreceptors 
in the proximal stomach. Therefore, delayed gastric emptying or altered fundic 
accommodation may contribute to increase triggering of TLESRs.  
5-HT4 agonists such as cisapride, mosapride and tegaserod are known to have 
gastroprokinetic effects and restore gastrointestinal dysmotility in subjects. It is reported 
that 5-HT4 agonists act through enhanced release of acetylcholine via 5-HT4 receptors at 
the postganglionic level result in the acceleration of gastrointestinal motility (24-26).  
Cisapride with a benzamide structure was released in the United States as Propulsid 
in 1993 and is available as Prepulsid in Europe and other countries. This agent is the 
first panprokinetic developed. Cisapride stimulates esophageal peristalsis, lower 
esophageal sphincter (LES) pressure, and gastric emptying (27-29), which explains its 
efficacy in GERD. This reducing gastric distention can lead to fewer TLESRs and less 
gastroesophageal reflux. Cisapride had also used for a variety of gastrointestinal 
complaints, including functional constipation, c-IBS and diabetic gastroparesis. 
However, cisapride was withdrawn from the market in 2000 due to its cardiovascular 
side effects (30). 
Mosapride with a benzamide structure was released in Japan as Gasmotin in 1998 and 
also in South Korea and China. Mosapride has been used for the treatment of 
gastrointestinal symptoms as heartburn, nausea and vomiting with chronic gastritis. 
Early clinical study indicated that mosapride promoted gastric emptying in healthy 
volunteers (31), enhanced gastric motility in diabetes (32). Ruth et al. (33) reported 
inhibition of GERD symptoms in 1998, but no further work has been reported in this 
area. 
Tegaserod with an aminoguanidine indole structure was released in Mexico as 
Zelnorm in 2001 and is available in other countries except for Western Europe for c-IBS 
and chronic constipation. Tegaserod also demonstrated the acceleration of gastric 
emptying in healthy volunteers (34) and the reduction of postprandial esophageal acid 
exposure result from decreased TLESR in GERD patients (35). 
 Although mosapride and tegaserod demonstrated gastroprokinetic effects, their 
indications are limited compared with those of cisapride. Therefore, there are unmet 
 - 3 -
needs in clinical therapy after the withdrawal of cisapride. A novel 5-HT4 agonist, 
CJ-033466 has been developed to fill the gap between them. CJ-033466 is an 
imidazopyridine derivative which is a different structure class from cisapride, 
mosapride and tegaserod. The isolated rat tunica muscularis mucosae (TMM) has 
proved to be useful in characterizing the pharmacology of 5-HT4 receptor agonists (36, 
37). In this functional assay, EC50 values of cisapride, mosapride, tegaserod and 
CJ-033466 for 5-HT4 receptors are 49, >1000, 0.15 and 1.3 nM, respectively (Fig. 1). 
Other than 5-HT4 agonism, it is reported that cisapride had 5-HT1 and 5-HT3 
antagonism (25), a metabolite of mosapride had 5-HT3 antagonism (38), and tegaserod 
had 5-HT2B antagonism (39).  
Therefore, the present study aims to profile the gastroprokinetic effect and the 
pharmacological characterization of CJ-033466 in in vivo canine gastric motility, rat 
gastric emptying and motility models and in vitro rat isolated circular muscle from the 
stomach compared with those of cisapride, mosapride and tegaserod. 
Regional and functional differences of 5-HT receptor subtypes in the rat stomach 
remains unclear except for 5-HT2B receptors on the fundus. Therefore, pharmacological 
characterization of 5-HT receptor subtypes in circular muscle from the antrum, corpus 
and fundus of rats were studied for clarifying the similarity and difference among the 
5-HT4 receptor agonists. 
Finally, the effect of CJ-033466 on acetylcholine release from human gastric antral 
tissues was evaluated in order to extrapolate the activity of CJ-033466 in humans.  
 
 
All animal experiments used in the present study (Chapter I to IV) were approved by the 
Animal Ethics Committee at the Nagoya Laboratories of Pfizer Global Research and 
Development according to the Laboratory Animal Welfare guidelines. All human tissue 
experiments in the present study (Chapter V) were approved by The Ethical Committee 
of Nagasaki University School of Medicine, based on the informed consent of patients. 
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 Figure 1. Chemical structures, potencies and efficacies of 5-HT4 agonists, cisapride, 
mosapride, tegaserod and CJ-033466. The potency and efficacy were examined 
with rat tunica muscularis mucosae (TMM).  - 5 -
Chapter I: Effects of 5-HT4 receptor agonists on gastric motility in dogs 
 
1. Introduction 
 
The dog stomach is anatomically similar to that of human. The patterns of 
gastrointestinal contractions in the interdigestive (fasted) and the digestive 
(postprandial) states of dogs are homologous to human (40, 41). Canine gastric motility 
and gastric emptying models are widely used to study the physiology of gastrointestinal 
tract and the effect of gastrokinetics on the stomach. It is known that the data from dogs 
are well extrapolated to human. 
The contractile patterns before and after feeding in dogs are quite different, which is 
also seen in the human gastrointestinal tract (42). In the fasted state, a group of intense 
phasic contractions occur in the stomach at about 90 min intervals and last for about 20 
min and then stop abruptly and spontaneously. These grouped, strong phasic 
contractions appear to immigrate along the small intestine in a caudal direction at a 
constant velocity, which called interdigestive migrating contraction (IMC) (43). It is 
generally accepted that motilin released in the fasted state induces IMC in dogs and 
humans (44). The fasted state is by no means a quiescent state after digestion and 
absorption are terminated, even then, desquamated epithelial cells, mucus, and saliva 
may accumulate in the stomach. The strong contractions are considered to move them 
into and down the small bowel and into the large bowel. Therefore, the IMC are 
regarded as the interdigestive ‘housekeeper’ of the gut. On the other hand, in the 
postprandial state, the gastric contractions are regular and continuous. The contraction 
force during the postprandial state is about one-third to one-fourth of that of the 
interdigestive contractions. After the ingestion of food, the contractile activity of the 
gastric body decreases to accommodate the food in the stomach. It has been called 
‘receptive relaxation’. In association with the receptive relaxation of the gastric body, 
regular and continuous contractions start to occur in the gastric antrum. These 
contractions grind and mix food with gastric secretion during the initial period and 
evacuate the mixture into the duodenum during the latter period. In the postprandial 
state, peptides such as gastrin, VIP, somatostatin and CCK are released from the 
stomach and duodenum and regulate gastric motility directly and indirectly (45-48). 
The dog gastric motility was measured using a strain gauge force transducer method. 
Strain gauge transducers have been used to record sustained contractions and 
relaxations as well as circular and longitudinal muscle phasic activity. When sewn along 
with the circular muscle of the stomach, the transducer records phasic contractions 
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which may be superimposed on tonal changes of circular muscle activity. The strain 
gauge transducer method has several advantages over other methods of gastrointestinal 
motility recording. The unit directly records the contractile activity of the smooth 
muscle. Strain gauge transducers are sewn on the serosal surface of the gastrointestinal 
tract. Therefore, there is no artificial effect on intraluminal conditions such as an 
interference with flow of intraluminal contents and stimulation of mucosal receptors. 
Since they are permanently fixed in position, the same site can be monitored repeatedly 
without using elaborated procedures to place the sensors in the desired position. 
Furthermore, it is well-known that gastrointestinal motility is influenced with 
anesthetics and under the stress. With telemetry system, gastrointestinal motility can be 
measured under fully conscious and minimal restraint conditions. 
In this chapter, considering the difference with the contractile pattern and 
mechanisms involving in the fasted and postprandial state, effects of 5-HT4 agonists 
were examined using the strain gauge force transducer method under the fasted and 
postprandial conditions in dogs. 
 
2. Materials and Methods 
 
Animals  
Male beagle dogs weighing 9.9-14.7 kg (Oriental Yeast Co., Ltd., Tokyo, Japan) were 
used. The animals were acclimatized to the laboratory conditions during experiments. 
 
Preparation of animals 
Dogs were anesthetized with isoflurane and the abdominal cavity was opened under 
aseptic conditions. Extraluminal force transducers (F-12IS, Star Medical, Tokyo, Japan) 
were sutured onto the seromuscular layer of the gastric antrum, (3 cm proximal to the 
pyloric ring), the gastric body (10-15 cm proximal to the pyloric ring), the duodenum 
(10 cm distal to the pyloric ring), and the proximal colon (5 cm distal to the ileocecum). 
The lead wires of these transducers were taken out of the abdominal cavity and then 
brought out through a skin incision made between the scapulae. After surgery, protective 
jackets were placed on the dogs, and they were housed in individual cages. Recording of 
the gastric motility was started at least 2 weeks after surgery. 
 
Experiments in the fasted state 
After an overnight fast, the dogs were placed in the shield room, and recording of 
gastrointestinal motility in the fasted state initiated. Gut motility was measured with a 
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telemetry system (GTS-800, Star Medical, Tokyo, Japan) and data acquired into a 
personal computer with the acquisition software (Eight Star, Star Medical, Tokyo, 
Japan). After confirmation of the incidence of interdigestive migrating contraction 
(IMC) at regular intervals, vehicle or a 5-HT4 receptor agonist was administered orally. 
Gut motility was then recorded for 8 h. 
 
Experiments in the postprandial state 
Recording of motility was started as same as the experiment in the fasted state.  
After confirmation of IMC, 100 g /animal (cisapride and CJ-033466 studies) or 10 g/kg 
(mosapride and tegaserod studies) of solid meal was given to the dog. Two hours after 
feeding, vehicle or a 5-HT4 receptor agonist was administered orally. Gut motility was 
then recorded for 6 h. 
 
Antagonist study 
SB-203186, a 5-HT4 receptor antagonist (10 mg/kg), or vehicle was subcutaneously 
administered one and a half hour after the fed. Thirty minutes later, CJ-033466 (0.1 
mg/kg) was orally administered. 
 
Analysis of data 
To quantify gastric motility, the areas of the contractions of the gastric antrum were 
determined by the processing software (Analyze II, Star Medical, Tokyo, Japan). In the 
fasted state study, the area surrounded by the contraction curve and the baseline for 
every 2 h period after administration was calculated. For standardization, the calculated 
areas were divided by the peak height of the last IMC before administration, and used as 
the motor index. In the postprandial state study, the area surrounded by the contraction 
curve and the baseline for every 1 h period after administration was calculated. For 
standardization, the calculated areas were divided by the area for 1 h period before 
administration, and expressed as a percentage. It was used as the motor index.  
 
Chemicals 
CJ-033466, cisapride, mosapride, tegaserod and SB-203186 were synthesized at 
Pfizer Inc. Methylcellulose (MC) was purchased from Shin-Etsu Chemical Co. (Tokyo, 
Japan).  
Cisapride, mosapride, tegaserod and CJ-033466 were suspended in 0.5% MC solution 
and administered orally at a volume of 5 mL. SB-203186 was dissolved in 0.9% saline 
at a volume of 0.2 mL/kg. 
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Statistics 
Data were presented as mean ± S.E.M. Statistical analysis was performed with 
Dunnett’s test using JMP software (SAS Institute Inc., Cary, NC, USA). P values of less 
than 0.05 were regarded as significant. 
 
3. Results 
 
Effects of 5-HT4 receptor agonists on gastric motility under the fasted state in dogs. 
Figure 2A shows the typical contractile patterns of the gastric antrum under fasted 
state in conscious dogs. The IMC was observed in intervals of approximately 90 min. 
Between the IMCs, few contractile activities were observed. Cisapride (0.3 – 3 mg/kg, 
p.o.) stimulated gastric motility in a dose-dependent manner (Fig. 3). The change in the 
motor index achieved statistical significance at the dose of 1 mg/kg during the 0 to 6 h 
period after administration. The stimulatory effect of cisapride 3 mg/kg lasted at least 8 
h after the administration. Mosapride (0.3 – 3 mg/kg, p.o.) did not stimulate gastric 
motility (Fig. 4). Tegaserod (0.03 – 0.3 mg/kg, p.o.) dose-dependently stimulated gastric 
motility (Fig. 5). At the dose of 0.1 mg/kg, the stimulatory effect during the 0 to 2 h 
period after administration was statistically significant. CJ-033466 (0.01 – 0.3 mg/kg, 
p.o.) stimulated gastric motility in a dose-dependent manner (Fig. 6). The change in the 
motor index achieved statistical significance at the dose of 0.03 mg/kg during the 0 to 2 
h period after administration. The stimulatory effect of CJ-033466 0.3 mg/kg lasted at 
least 8 h after administration. 
 
Effects of 5-HT4 receptor agonists on gastric motility under the postprandial state in 
dogs. 
Figure 2C shows the typical contractile patterns of the gastric antrum under the 
postprandial state in conscious dogs. Approximately 8 h after feeding, the contractile 
pattern of postprandial state gradually changed to an irregular pattern, thereafter showed 
IMC-like strong contractions. Cisapride (0.3 – 3 mg/kg, p.o.) dose-dependently 
stimulated gastric motility (Fig. 7). At the dose of 1 mg/kg, the change in the motor 
index achieved statistical significance during the 0 to 4 h period. Mosapride (0.3 – 3 
mg/kg, p.o.) stimulated gastric motility in a dose-dependent manner (Fig. 8). At the dose 
of 3 mg/kg, the stimulatory effect reached statistical significance during the 0 to 1 h and 
2 to 4 h periods. Tegaserod (0.1 – 1 mg/kg, p.o.) stimulated gastric motility in a 
dose-dependent manner (Fig. 9). At the dose of 1 mg/kg, the stimulatory effect reached 
statistical significance during the 0 to 5 h period. CJ-033466 (0.01 – 0.3 mg/kg, p.o.) 
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dose-dependently stimulated gastric motility (Fig. 10). At the dose of 0.03 mg/kg, the 
stimulatory effect was statistically significant during the 1 to 3 h period. The stimulatory 
effect of CJ-033466 reached maximum at the dose of 0.1 mg/kg, which lasted 5 h after 
administration. 
 
Effect of SB-203186 on CJ-033466-stimulated gastric motility in the postprandial state. 
Pretreatment of SB-203186 (10 mg/kg, s.c.) completely blocked CJ-033466 (0.1 
mg/kg, p.o.)-stimulated gastric motility (Fig. 11).  
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 Figure 2. Typical contractile patterns of the gastric antrum in conscious dogs. 
Effect of CJ-033466 (0.1 mg/kg, B, D) or vehicle (0.5% methylcellulose 5 
mL/kg, A, C) on gastric motility under the fasted and postprandial states.  - 11 -
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 Figure 3. Effect of cisapride on gastric motility under the fasted state in conscious 
dogs. Cisapride or vehicle (0.5% methylcellulose) was orally administrated. 
Changes in gastric motility were expressed by the motor index. The motor index 
was shown as relative AUC of the gastric motility for every 2 h period after the 
administration in which the peak height of the last interdigestive migrating 
contraction before the administration. Data are expressed as mean ± S.E.M. from 
4 to 5 animals. *: P<0.05, **: P<0.01, compared with vehicle-treated group 
(Dunnett’s test). - 12 -
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 Figure 4. Effect of mosapride on gastric motility under the fasted state in conscious 
dogs. Mosapride or vehicle (0.5% methylcellulose) was orally administrated. 
Changes in gastric motility were expressed by the motor index. The motor index 
was shown as relative AUC of the gastric motility for every 2 h period after the 
administration in which the peak height of the last interdigestive migrating 
contraction before the administration. Data are expressed as mean ± S.E.M. from 
4 animals.  - 13 -
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 Figure 5. Effect of tegaserod on gastric motility under the fasted state in conscious 
dogs. Tegaserod or vehicle (0.5% methylcellulose) was orally administrated. 
Changes in gastric motility were expressed by the motor index. The motor index 
was shown as relative AUC of the gastric motility for every 2 h period after the 
administration in which the peak height of the last interdigestive migrating 
contraction before the administration. Data are expressed as mean ± S.E.M. from 
4 animals. *: P<0.05, **: P<0.01, compared with vehicle-treated group (Dunnett’s 
test). - 14 -
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 Figure 6. Effect of CJ-033466 on gastric motility under the fasted state in conscious 
dogs. CJ-033466 or vehicle (0.5% methylcellulose) was orally administrated. 
Changes in gastric motility were expressed by the motor index. The motor index 
was shown as relative AUC of the gastric motility for every 2 h period after the 
administration in which the peak height of the last interdigestive migrating 
contraction before the administration. Data are expressed as mean ± S.E.M. from 
4 to 5 animals. *: P<0.05, **: P<0.01, compared with vehicle-treated group 
(Dunnett’s test). - 15 -
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 Figure 7. Effect of cisapride on gastric motility under the postprandial state in 
conscious dogs. After the confirmation of interdigestive migrating contraction, a 
solid meal was given the dog. Two hours after feeding, cisapride or vehicle (0.5% 
methylcellulose) was orally administrated. Changes in gastric motility were 
expressed by the percentage of motor index. The motor index was shown as relative 
AUC of the gastric motility for every 1 h period after the administration in which 
AUC of 1 h period before the administration was taken as 100%. Data are 
expressed as mean ± S.E.M. from 4 to 5 animals. *: P<0.05, **: P<0.01, 
compared with vehicle-treated group (Dunnett’s test). - 16 -
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 Figure 8. Effect of mosapride on gastric motility under the postprandial state in 
conscious dogs. After the confirmation of interdigestive migrating contraction, a 
solid meal was given the dog. Two hours after feeding, mosapride or vehicle (0.5% 
methylcellulose) was orally administrated. Changes in gastric motility were 
expressed by the percentage of motor index. The motor index was shown as relative 
AUC of the gastric motility for every 1 h period after the administration in which 
AUC of 1 h period before the administration was taken as 100%. Data are 
expressed as mean ±  S.E.M. from 4 animals. *: P<0.05, compared with 
vehicle-treated group (Dunnett’s test). - 17 -
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 Figure 9. Effect of tegaserod on gastric motility under the postprandial state in 
conscious dogs. After the confirmation of interdigestive migrating contraction, a 
solid meal was given the dog. Two hours after feeding, tegaserod or vehicle (0.5% 
methylcellulose) was orally administrated. Changes in gastric motility were 
expressed by the percentage of motor index. The motor index was shown as relative 
AUC of the gastric motility for every 1 h period after the administration in which 
AUC of 1 h period before the administration was taken as 100%. Data are 
expressed as mean ± S.E.M. from 4 animals. *: P<0.05, **: P<0.01, compared 
with vehicle-treated group (Dunnett’s test). - 18 -
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 Figure 10. Effect of CJ-033466 on gastric motility under the postprandial state in 
conscious dogs. After the confirmation of interdigestive migrating contraction, a 
solid meal was given the dog. Two hours after feeding, CJ-033466 or vehicle (0.5% 
methylcellulose) was orally administrated. Changes in gastric motility were 
expressed by the percentage of motor index. The motor index was shown as relative 
AUC of the gastric motility for every 1 h period after the administration in which 
AUC of 1 h period before the administration was taken as 100%. Data are 
expressed as mean ± S.E.M. from 4 to 5 animals. *: P<0.05, **: P<0.01, 
compared with vehicle-treated group (Dunnett’s test). - 19 -
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 Figure 11. Effect of SB-203186 on CJ-033466-stimulated gastric motility under the 
postprandial state in conscious dogs. After the confirmation of interdigestive 
migrating contraction, a solid meal was given the dog. (A) Vehicle (0.9% saline 0.2 
mL/kg) or (B) SB-203186 (10 mg/kg) was subcutaneously administered 1.5 h after 
feeding. Thirty minutes later, CJ-033466 (0.1 mg/kg) was orally administrated.  - 20 -
4. Discussion 
 
  In this chapter, cisapride, tegaserod and CJ-033466 dose-dependently stimulated 
gastric motility under both fasted and postprandial states in conscious dogs. Mosapride 
only stimulated gastric motility under the postprandial state. Potencies to stimulatory 
effect on gastric motility are CJ-033466 > tegaserod > cisapride in the fasted state and 
CJ-033466 > tegaserod = cisapride > mosapride in the postprandial state. The 
stimulatory effect of CJ-033466 was completely blocked by a 5-HT4 receptor antagonist, 
SB-203186. This result indicates that CJ-033466 stimulate gastric motility via 5-HT4 
receptors. 
  The enhancement of gastric motility by cisapride under both fasted and postprandial 
states in conscious dogs is well reported (49-52). In these reports, cisapride was 
administrated intravenously and marked stimulatory effect was observed at doses above 
0.1 mg/kg. Tanaka et al. (53) reported that intraduodenal administration of cisapride 
significantly enhanced gastric motility under the postprandial state in conscious dogs at 
the dose of 1 mg/kg. This potency is consistent with the present results using oral 
administration. Pretreatment of atropine or hexamethonium in the fasted state, or 
GR113808 (5-HT4 receptor antagonist) in the postprandial state completely inhibited 
gastroprokinetic effect of cisapride (49, 51, 52), suggesting the involvement of 
preganglionic cholinergic neurons and 5-HT4 receptors in the stimulatory effect of 
cisapride. 
  The effect of tegaserod on the upper gastrointestinal tract has not been intensively 
studied. In the present study, tegaserod demonstrated apparent stimulatory effect on 
gastric motility which is more potent than that of cisapride. The stimulatory effect of 
tegaserod on gastric motility was statistically significant at 0.1 and 1 mg/kg, p.o. in the 
fasted and postprandial states, respectively. When tegaserod was taken with food, the 
absorption was slowed and the AUC value was reduced approximately 2-fold in humans 
(54, 55). This food effects may influence on the potency of tegaserod under the 
postprandial state. 
  The stimulatory effect of mosapride on gastric motility was only observed under the 
postprandial state. Consistent with this result, gastroprokinetic effect of mosapride 
under the postprandial state was reported with intravenous or intraduodenal 
administration (51, 56). They reported that the stimulatory effect of mosapride was 
blocked by atropine or GR113808, but the stimulatory effect was observed in vagally 
denervated pouch. These results indicated the involvement of the postganglionic 
cholinergic neurons and 5-HT4 receptors in the stimulatory effect of mosapride. Yoshida 
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et al. (56) suggested that different neurological pathway involved with cisapride and 
mosapride is due to their different pharmacological profile. This discrepancy may also 
depend on the gastric motility induced under different feeding conditions, fasted or fed. 
Mosapride did not stimulate gastric motility under the fasted state. The functional 
activity of mosapride on the isolated rat TMM is weak in in-house data (Fig. 1). Mine et 
al. (51) also reported that EC50 values of mosapride and cisapride on rat TMM is 208 
and 39 nM, respectively. In addition, mosapride enhanced the electrically evoked 
contractions of guinea pig ileum and evoked the contractions of guinea pig distal colon 
with EC50 values of 73 and 3029 nM, respectively. Those of EC50 values of cisapride are 
48 and 32 nM, respectively (51). These results indicate that mosapride may need a 
pre-stimulated condition to demonstrate its activity. Therefore, a dose higher than 3 
mg/kg may be needed to stimulate the gastric motility under fasted condition. Another 
reason for the inactivity of mosapride under fasted state is the presence of a metabolite 
of mosapride. It is reported that the major metabolite of mosapride has potent 5-HT3 
receptor antagonistic activity (38). 5-HT3 receptor antagonists inhibited the IMC in the 
fasted state and did not influence gastric motility in the postprandial state (57). 
Therefore, 5-HT3 antagonism of the metabolite may block the stimulatory effect of 
mosapride in the fasted state. 
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Chapter II: Effects of 5-HT4 receptor agonists on gastric emptying and gastric 
motility in rats 
 
1. Introduction 
 
5-HT4 receptor agonists demonstrate the enhancement of canine gastric motility, 
except for mosapride in the fasted state, in Chapter I. Although most of the time 
enhancement of gastric motility correlates the acceleration of gastric emptying, the 
number and/or force of contractions are increased does not mean that empting is 
enhanced. Antropyloroduodenal incoordination or retrograde peristalsis may impair 
gastric emptying. It is important to understand the correlation between gastric motility 
and gastric emptying. Thus, in this chapter, both rat gastric emptying and gastric 
motility models are used to investigate the efficacy of 5-HT4 receptor agonists. 
The isolated rat TMM is generally used for examining the 5-HT4 receptor agonist 
activity (36, 37). Not only in-house data, but also cisapride, mosapride and tegaserod 
data are reported in this functional assay (39, 51). In the present experiment, comparison 
of in vitro and in vivo data from rats was performed, in order to clarify the properties of 
5-HT4 receptor agonists. 
The blockade of 5-HT3 receptor inhibits gastric motility under the fasted state in dogs 
(57) and humans (58). In contrast, the blockade of 5-HT3 receptor accelerates gastric 
emptying in rats (59-61). Unlikely, mosapride did not stimulate canine gastric motility 
under the fasted state. One of the reasons for the lack of stimulatory effect of mosapride 
may be the 5-HT3 antagonism of its metabolite. The result from rat gastric emptying 
study using 5-HT4 receptor antagonist may clarify the reason.  
In this chapter, effects of cisapride, mosapride, tegaserod and CJ-033466 on gastric 
emptying and gastric antral motility in free moving conscious rats were examined and 
the correlation between them was evaluated. In addition, effects of ondansetron (5-HT3 
receptor antagonist) and α-methyl-5-HT (5-HT2 receptor agonist) were examined to 
understand the results from cisapride, mosapride, tegaserod and CJ-033466. 
 
2. Materials and Methods 
 
Animals  
Male Crj:SD(IGS) rats weighing 185-255 g (Charles River Japan, Inc., Shiga, Japan) 
were used. The animals were maintained on ordinary laboratory chow and tap water ad 
libitum under a constant 12-hr light-dark cycle. 
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Gastric emptying in rats 
Rats were fasted overnight with free access to water. Water was deprived 2 hr before 
starting the experiment. A semi-solid meal (methylcellulose: 7 g, glucose: 7.5 g, 
cornstarch: 9 g, casein: 15 g in 275 ml of water) 3 mL/head was given orally. Thirty 
minutes later, rats were euthanized with CO2. The stomach was exposed through 
laparotomy, quickly ligated at both pylorus and cardia, then removed and weighed. The 
stomach was opened and rinsed with saline, and weighed again. Gastric emptying rate 
was calculated the following formula. Gastric emptying rate (%) = (1-Weight of meal 
left in the stomach / Weight of given meal) x 100. Cisapride, mosapride, tegaserod 
ondansetron or vehicle was orally administered to rats 15 min before the semi-solid 
meal administration. CJ-033466 or vehicle was orally administered to rats 5 min before 
the semi-solid meal administration. Alpha-methyl-5-HT or vehicle was intravenously 
administered to rats 10 min before the semi-solid meal administration.  
In order to evaluate the effect of SB-203186 on gastrokinetic effects of 5-HT4 
agonists, SB-203186 (10 mg/kg), or vehicle was subcutaneously administered to rats 5 
min before the 5-HT4 receptor agonist administration.  
 
Gastric motility in rats 
Rats were fasted overnight with free access to water before an abdominal operation. 
Animals were anaesthetized with ketamine 50 mg/xylazin 20 mg/kg i.m. and motility 
recording device was implanted as follows. A manometric catheter and a catheter for 
intragastric administration (Intravenous catheter: 3Fr, 1 mm diameter, ATOM, Tokyo, 
Japan) were inserted through the fistula in the gastric body and the tips placed at the 
gastric antrum. Catheters were fixed to the gastric wall by sutures, which ran 
subcutaneously to emerge at the top of the neck and were secured at the animal’s skin. A 
catheter (Indwelling feeding tube: 3Fr, 1 mm diameter, ATOM, Tokyo, Japan) was also 
placed in the left femoral vein. This ran subcutaneously to emerge at the top of the neck 
beside the manometric catheter, and used for i.v. administration. Animals were allowed 
to recover for 1 week before the measurement of gastric motility.  
For measurement of gastric antal motility, rats were fasted overnight with free access 
to water. Gastric antral motility was measured in conscious, freely moving rats by a 
manometric method. On the day of the experiment, the manometric catheter was 
connected to a pressure transducer (DX-100: Nihon Koden, Tokyo, Japan) and 
continuously infused with distilled water at a rate of 3 mL/h by a low-compliance 
capillary infusion system using pressure cuff. The data was recorded and stored in a 
PowerLab system (ADInstruments Pty Ltd, Castle Hill, Australia). After recording the 
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basal gastric motility for at least 30 min, SB-203186 or vehicle was administered 
intravenously. Five minutes later, cisapride, mosapride, tegaserod or CJ-033466 was 
administered into the stomach. Then gastric motility was continuously measured for 60 
min. For ondansetron, the protocol was the same as the 5-HT4 agonist study, except for 
without i.v. administration.  
To quantify gastric motility, the areas of the contractions of the gastric antrum were 
determined by the PowerLab system. The area surrounded by the contraction curve and 
the baseline for every 5 min period after the first administration (i.v. or i.g.) was 
calculated. For standardization, on the period before the first drug administration, the 
average of the 15 min area was calculated and expressed as 5 min period. It was used as 
the motor index. 
 
Chemicals 
Cisapride, mosapride, tegaserod, CJ-033466, ondansetron and SB-203186 were 
synthesized at Pfizer Inc. Alpha-methyl-5-HT maleate was purchased from Sigma (St. 
Louis, MO, USA). Casein was purchased from Sigma-Aldrich Japan (Tokyo, Japan). 
Methylcellulose (for test meal), D(+)-glucose and cornstarch were purchased from 
Wako pure chemical (Osaka, Japan). Methylcellulose (MC) for vehicle was purchased 
from Shin-Etsu Chemical Co. (Tokyo, Japan). 
Cisapride, mosapride, tegaserod, CJ-033466 and ondansetron were suspended with 
0.5% MC in water at a volume of 2 mL/kg. SB-203186 and α-methyl-5-HT were solved 
with 0.9% saline at a volume of 2 mL/kg. 
 
Statistics 
Data were presented as mean ± S.E.M. For the gastric emptying dose-response study, 
the comparison between the control group and the treated group was carried out by 
one-way analysis of variance (ANOVA) with Dunnett’s test. For the gastric emptying 
antagonist study, the comparison between the control group and the antagonist-treated 
group was carried out by unpaired t-test with Welch's correction. P values of less than 
0.05 were regarded as significant. 
 
3. Results 
 
Effects of 5-HT4 receptor agonists on gastric emptying. 
Cisapride (0.1 – 3 mg/kg, p.o.) accelerated gastric emptying in a dose-dependent 
manner (Fig. 12). Acceleratory effects of cisapride were statistically significant at doses 
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of 1 and 3 mg/kg. Mosapride (0.1 – 3 mg/kg, p.o.) dose-dependently accelerated gastric 
emptying (Fig. 13). At the dose of 0.3 mg/kg, stimulatory effect of mosapride reached 
statistically significant. Maximal effect was observed at 1 mg/kg. On the other hand, 
tegaserod (0.1 – 3 mg/kg, p.o.) did not accelerate gastric emptying (Fig. 14). CJ-033466 
accelerated gastric emptying in a dose-dependent manner (Fig. 15). At the dose of 3 
mg/kg, stimulatory effect of CJ-033466 was statistically significant. 
 
Effects of SB-203186 on 5-HT4 receptor agonists-accelerated gastric emptying. 
Pretreatment with SB-203186 (1 – 10 mg/kg, s.c.) inhibited cisapride (3 mg/kg, 
p.o.)-accelerated gastric emptying (Fig. 16). At the dose of 10 mg/kg, SB-203186 
completely inhibited the stimulatory effect of cisapride. Therefore the following 
antagonist study, 10 mg/kg of SB-203186 was pretreated. SB-203186 inhibited both 
mosapride (1 mg/kg, p.o.) and CJ-033466 (3 mg/kg, p.o.)-accelerated gastric emptying 
(Figs. 17, 18). SB-203186 delayed gastric emptying treated with tegaserod (3 mg/kg, 
p.o.), but was not statistically significant (Fig. 17). 
 
Effects of ondansetron and α-methyl-5-HT on gastric emptying. 
  Ondansetron (0.1 – 3 mg/kg, p.o.) accelerated gastric emptying significantly (Fig. 19). 
At the dose of 0.1 mg/kg, the stimulatory effect already reached the maximum. 
Alpha-methyl-5-HT (0.01 – 1 mg/kg, i.v.) did not accelerate gastric emptying (Fig. 20). 
 
Effects of 5-HT4 receptor agonists on gastric motility. 
Cisapride (3 mg/kg, i.g.) markedly stimulated gastric motility (Fig. 21). Mosapride (1 
mg/kg, i.g.) stimulated gastric motility (Fig. 22), but tegaserod (3 mg/kg, i.g.) did not 
show any effect on gastric motility (Fig. 23). CJ-033466 (3 mg/kg, i.g.) stimulated 
gastric motility (Fig. 24). The stimulatory effect of CJ-033466 was short duration of 
action. 
 
Effects of SB-203186 on 5-HT4 receptor agonists-stimulated gastric motility. 
SB-203186 (10 mg/kg, i.v.) slightly increased gastric motility at 30 to 40 min after 
the administration. Pretreatment with SB-203186 (10 mg/kg, i.v.) completely inhibited 
cisapride (3 mg/kg, p.o.), mosapride (1 mg/kg, p.o.) or CJ-033466 (3 mg/kg, 
p.o.)-stimulated gastric motility (Figs. 21 - 24).  
 
Effects of ondansetron and α-methyl-5-HT on gastric motility. 
  Ondansetron (1 mg/kg, p.o.) did not influence gastric motility (Fig. 25). Preliminary 
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data, α-methyl-5-HT (0.3mg/kg, i.v.) increased gastric motility (Fig. 26, n = 1). 
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 Figure 12. Effect of cisapride on gastric emptying in conscious rats. Cisapride or
vehicle was orally administered to rats 15 min before test meal administration.
Data are expressed as mean ±  S.E.M. from 6 to 8 animals. **: P<0.01,
compared with vehicle-treated group (One-way ANOVA followed by the
Dunnett’s test). - 28 -
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 Figure 13. Effect of mosapride on gastric emptying in conscious rats. Mosapride
or vehicle was orally administered to rats 15 min before test meal administration.
Data are expressed as mean ±  S.E.M. from 6 to 8 animals. **: P<0.01,
compared with vehicle-treated group (One-way ANOVA followed by the
Dunnett’s test). - 29 -
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 Figure 14. Effect of tegaserod on gastric emptying in conscious rats. Tegaserod or
vehicle was orally administered to rats 15 min before test meal administration.
Data are expressed as mean ± S.E.M. from 6 to 7 animals.  - 30 -
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 Figure 15. Effect of CJ-033466 on gastric emptying in conscious rats. CJ-033466
or vehicle was orally administered to rats 5 min before test meal administration.
Data are expressed as mean ±  S.E.M. from 7 to 8 animals. **: P<0.01,
compared with vehicle-treated group (One-way ANOVA followed by the
Dunnett’s test). - 31 -
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 Figure 16. Effect of SB-203186 on the gastrokinetic response to cisapride in
conscious rats. SB-203186 or 0.9% saline was subcutaneously injected to rats 20 
min before test meal administration. Cisapride or 0.5% methylcellulose (MC) was 
orally administered to rats 15 min before test meal administration. Data are 
expressed as mean ± S.E.M. from 5 to 7 animals. ##: P<0.01, compared with 
saline s.c. and 0.5% MC p.o.-treated group (Unpaired t-test with Welch’s correction). 
*: P<0.05, **: P<0.01, compared with 0.9% saline s.c and cisapride p.o.-treated 
group (One-way ANOVA followed by the Dunnett’s test). - 32 -
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 Figure 17. Effect of SB-203186 on the gastrokinetic response to cisapride, tegaserod
or mosapride in conscious rats. SB-203186 or 0.9% saline was subcutaneously
injected to rats 20 min before test meal administration. Cisapride, tegaserod, 
mosapride or 0.5% methylcellulose (MC) was orally administered to rats 15 min
before test meal administration. Data are expressed as mean ± S.E.M. from 5 to 7 
animals. ##: P<0.01, compared with 0.9% saline s.c. and 0.5% MC p.o.-treated 
group. **: P<0.01, compared with saline s.c and cisapride or mosapride p.o.-treated 
group (Unpaired t-test with Welch’s correction). - 33 -
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 Figure 18. Effect of SB-203186 on the gastrokinetic response to CJ-033466 in 
conscious rats. SB-203186 or 0.9% saline was subcutaneously injected to rats 10 
min before test meal administration. CJ-033466 or 0.5% methylcellulose (MC) was 
orally administered to rats 5 min before test meal administration. Data are expressed 
as mean ± S.E.M. from 7 to 8 animals. ##: P<0.01, compared with 0.9% saline 
s.c. and 0.5% MC p.o.-treated group. **: P<0.01, compared with saline s.c and 
CJ-033466 p.o.-treated group (Unpaired t-test with Welch’s correction). - 34 -
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 Figure 19. Effect of ondansetron on gastric emptying in conscious rats. Ondansetron 
or vehicle was orally administered to rats 15 min before test meal administration.
Data are expressed as mean ± S.E.M. from 6 to 8 animals. *: P<0.05, **: P<0.01, 
compared with vehicle-treated group (One-way ANOVA followed by the Dunnett’s 
test). - 35 -
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 Figure 20. Effect of α-methyl-5HT on gastric emptying in conscious rats. 
α-methyl-5HT or vehicle was intravenously injected to rats 10 min before test meal 
administration. Data are expressed as mean ± S.E.M. from 6 to 8 animals.  - 36 -
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 Figure 21. Effect of cisapride on gastric motility in conscious rats. Cisapride (3 
mg/kg) or vehicle (0.5% methylcellulose 2 mL/kg) was intragastricaly administered 
at 0 min. Five minutes before the administration, SB-203186 (10 mg/kg) or 0.9% 
saline (2 mL/kg) was intravenously administered. Data are expressed as mean ± 
S.E.M. from 3 to 4 animals.  - 37 -
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 Figure 22. Effect of mosapride on gastric motility in conscious rats. Mosapride (1 
mg/kg) or vehicle (0.5% methylcellulose 2 mL/kg) was intragastricaly administered 
at 0 min. Five minutes before the administration, SB-203186 (10 mg/kg) or 0.9% 
saline (2 mL/kg) was intravenously administered. Data are expressed as mean ± 
S.E.M. from 3 to 4 animals.  - 38 -
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 Figure 23. Effect of tegaserod on gastric motility in conscious rats. Tegaserod (3 
mg/kg) or vehicle (0.5% methylcellulose 2 mL/kg) was intragastricaly administered 
at 0 min. Five minutes before the administration, SB-203186 (10 mg/kg) or 0.9% 
saline (2 mL/kg) was intravenously administered. Data are expressed as mean ± 
S.E.M. from 3 to 4 animals.  - 39 -
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 Figure 24. Effect of CJ-033466 on gastric motility in conscious rats. CJ-033466 (3 
mg/kg) or vehicle (0.5% methylcellulose 2 mL/kg) was intragastricaly administered 
at 0 min. Five minutes before the administration, SB-203186 (10 mg/kg) or 0.9% 
saline (2 mL/kg) was intravenously administered. Data are expressed as mean ± 
S.E.M. from 3 to 4 animals.  - 40 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-30 -20 -10 0 10 20 30 40 50 60
0
100
200
300
400
Time (min)
M
ot
or
 in
de
x 
(%
)
ig
Control
Ondansetron i.g.
M
ot
or
 in
de
x 
(%
)
M
ot
or
 in
de
x 
(%
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 25. Effect of ondansetron on gastric motility in conscious rats. Ondansetron 
(1 mg/kg) or vehicle (0.5% methylcellulose 2 mL/kg) was intragastricaly 
administered at 0 min. Five minutes before the administration, 0.9% saline (2 
mL/kg) was intravenously administered for control group. Data are expressed as
mean ± S.E.M. from 3 to 4 animals.  - 41 -
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 Figure 26. Effect of α-methyl-5HT on gastric motiltiy in conscious rats. 
α-methyl-5HT was intravenously administered.  - 42 -
4. Discussion 
 
  In this chapter, cisapride, mosapride and CJ-033466 dose-dependently accelerated 
gastric emptying in conscious rats. However, tegaserod did not accelerate gastric 
emptying. Potencies to stimulatory effect on gastric emptying are mosapride > cisapride 
> CJ-033466. Consistent with this result, oral administration of mosapride demonstrated 
comparable or slight potent acceleratory effect than cisapride on gastric emptying in 
normal rats (62, 63). In these report, at a dose of 1 mg/kg of mosapride and cisapride 
reached statistical significant. With intravenous administration, cisapride-accelerated 
gastric emptying was observed approximately 10 times less dose than that of mosapride 
(61). This result consists with in vitro potency (51). Both cisapride and mosapride 
stimulated gastric antral motility. These results correlated with acceleratory effects on 
gastric emptying. On the other hand, CJ-033466 accelerated gastric emptying 
significantly, but the potency is 3 times less than that of cisapride. CJ-033466 
demonstrated the potent but short-lasting stimulatory effect on gastric antral motility. 
This short duration of action may result in the weak potency of CJ-033466 in rats. 
  It is reported that mosapride restored cisplatin-induced delayed gastric emptying (63). 
This effect was stronger than that of cisapride. Cisplatin is an antineoplastic agent, 
which induce side effects of nausea and emesis in clinical due to activation of 5-HT3 
receptors located in the gastrointestinal tract and/or central nervous system (64, 65). A 
metabolite of mosapride has 5-HT3 antagonism which potency is estimated to be 
20-fold less than a 5-HT3 antagonist, ondansetron (38, 66). However, in the present 
study, pretreatment with SB-203186, a 5-HT4 receptor antagonist, completely blocked 
mosapride-stimulated gastric emptying and gastric antral motility, indicating that 
stimulatory effect of mosapride mainly induced via 5-HT4 receptors. From these results, 
it may suggest that mosapride did not stimulate canine gastric motility under the fasted 
state due to low activity on basal condition.  
  SB-203186 also completely blocked cisapride- and CJ-033466-accelerated gastric 
emptying and gastric antral motility. The stimulatory effects of cisapride and CJ-033466 
may be induced via 5-HT4 receptors.  
  Tegaserod stimulated neither gastric emptying nor gastric antral motility in conscious 
rats. SB-203186 delayed tegaserod-treated gastric emptying, suggesting that tegaserod 
accelerated gastric emptying in some part via 5-HT4 receptors. Other than 5-HT4 
agonism, tegaserod may have pharmacological mechanism to delay gastric emptying. 
Recent study has revealed that tegaserod has a potent 5-HT2B antagonism which is 
comparable to 5-HT4 agonism (39). The 5-HT2B receptor was first discovered on rat 
 - 43 -
fundic longitudinal muscles and has been well characterized (67-69). 5-HT-induced 
fundic contractions were blocked by 5-HT2B receptor antagonists. Therefore, tegaserod 
may retain the administrated meal in the fundus via 5-HT2B antagonism. In order to 
confirm this hypothesis, effect of α-methyl-5-HT, a 5-HT2 agonist on gastric emptying 
was examined. Although a systemic side effect was observed in rats at the dose of 1 
mg/kg, i.v. of α-methyl-5-HT, up to this dose, α-methyl-5-HT did not accelerate gastric 
emptying. At the dose of 0.3 mg/kg, α-methyl-5-HT stimulated gastric antral motility in 
the preliminary data. Consistent with this result, Beattie et al. (39) also reported 
α-methyl-5-HT-induced fundic contractions in anesthetized rats. Antropyloroduodenal 
incoordination like pylorus sphincter contraction may occur. However, further studies 
are needed to clarify why α-methyl-5-HT-stimulated gastric motility did not accelerate 
gastric emptying in rats. 
  On the other hand, ondansetron enhanced gastric emptying significantly, but did not 
stimulate gastric antral motility. Not only ondansetron but also other 5-HT3 antagonists 
are known to increase the rate of gastric emptying in rats (59-61). Pretreatment with 
atropine or tetrodotoxin (TTX) abolished these gastric emptying accelerations, 
indicating the participation of cholinergic neurons (59). Generally, the stimulation of 
cholinergic neurons induces enhancement of gastric motility. Ondansetron may 
stimulate other regions of gastric motility to accelerate gastric emptying. 
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Chapter III: Pharmacological characterization of 5-HT-receptor subtypes in 
circular muscle from the rat stomach 
 
1. Introduction 
 
It is generally accepted that gastric emptying is regulated by the coordination of the 
proximal and distal stomach motilities. 5-HT has proven to be an important mediator of 
gastrointestinal motility (70, 71). The stimulation of 5-HT1B/1D receptors induces gastric 
accommodation in humans (22) and dogs (72) and delays gastric emptying in humans 
(73, 74). The blockade of 5-HT3 receptors inhibits gastrointestinal motility in humans 
(58). In addition, the stimulation of 5-HT4 receptors elicits gastrointestinal contractile 
activity and increases the rate of gastric emptying in humans (75, 76) and dogs (50, 77, 
78, Chapter I). With regard to gastric smooth muscle activity, it is generally accepted 
that the 5-HT1B/1D and 5-HT7 receptors are relaxant whereas the 5-HT2, 5-HT3, and 
5-HT4 receptors are contractile. Although the gastric contractility of 5-HT has been 
reported in a variety of species and stomach regions, regional and functional differences 
of 5-HT-receptor subtypes have been fully investigated only in the guinea pig stomach 
(79-82). In the guinea pig stomach, the fundus presents the relaxant 5-HT1 receptors and 
the contractile 5-HT2 and 5-HT3 receptors, the corpus presents the relaxant 5-HT1 
receptors and the contractile 5-HT3 and 5-HT4 receptors, and the antrum presents the 
contractile 5-HT2, 5-HT3 and 5-HT4 receptors. However, the in vivo studies for 
examining gastric motility and gastric emptying using guinea pigs are limited. On the 
other hand, the rat is widely used as in vivo models to study gastric motility (39, 83, 84) 
and gastric emptying rate (59, 62, 85). The stimulation of 5-HT2 receptors increases 
gastric motility (39), the blockade of 5-HT3 receptors accelerates gastric emptying (59), 
and the stimulation of 5-HT4 receptors increases gastric motility (83) and accelerates 
gastric emptying (59, 62). These findings are also reported in Chapter II. In in vitro, 
pharmacological characterization of the contractile response to 5-HT in the rat stomach 
regions still remains unclear, except for the contractile 5-HT2B receptors in longitudinal 
muscle strips of the fundus (67-69). This chapter was, therefore, designed to provide 
further information regarding functions of 5-HT receptor subtypes in circular muscle 
strips from the antrum, corpus and fundus of the rat stomach. 
 
2. Materials and Methods 
 
Preparation of smooth muscle strips from the rat stomach 
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Male Crj:SD (IGS) rats (Charles River Japan, Inc., Shiga, Japan) weighing 300-400 g 
were euthanized with Isoflurane inhalation. The stomach was excised and immediately 
cut into strips of fundus, corpus and antrum, in a circular fashion. The mucosa was 
removed from the tissue and muscle layers. 
 
Measurements of mechanical activity 
The strips of fundus, corpus or antrum were placed into a 10-mL organ bath 
containing Krebs-Ringer solution of the following composition: 118 mM NaCl, 4.8 mM 
KCl, 2.5 mM CaCl2, 1.19 mM MgSO4, 25.0 mM NaHCO3, 1.18 mM KH2PO4, 11 mM 
glucose and 0.12 mM ascorbic acid, oxygenated with 95% O2 and 5% CO2 and 
maintained at 37℃. Approximately 1 g of resting tension was applied, and the tension 
was kept constant by re-adjustment during the 60-min equilibration period. Mechanical 
responses were recorded by means of an isometric transducer (TB-612T; Nihon Kohden, 
Tokyo, Japan). Single doses of agonists were applied and then washed out on an interval 
of 30 to 35 min. To evaluate the effects of antagonists, the tissue strips were exposed to 
the antagonists 10 min before and during application of agonists; the applied dose of 
each antagonist was determined according to our preliminary trials or the doses used in 
the literature. The concentration-response curves of agonists were performed in 
concentrations from 3 x 10-9 to 3 x 10-6 M for the fundic strip and from 3 x 10-7 to 3 x 
10-4 M for the corporal and antral strips. Amplitudes of contraction and relaxation are 
represented relative to amplitude of contraction elicited by 10-5 M carbachol. 
 
Chemicals 
Carbachol (CCh), atropine sulfate monohydrate and tetrodotoxin (TTX) were 
purchased from Wako Pure Chemicals (Osaka, Japan). 5-Hydroxytryptamine 
hydrochloride (5-HT), Nω-Nitro-L-arginine (L-NOARG, NO synthetase inhibitor), 
methysergide maleate, ketanserin tartrate and SB-269970 (selective 5-HT7 receptor 
antagonist) were purchased from Sigma (St. Louis, MO, U.S.A.). WAY-100635 maleate 
(selective 5-HT1A receptor antagonist), GR127935 hydrochloride (5-HT1B/1D receptor 
antagonist) and cinanserin hydrochloride (selective 5-HT2 receptor antagonist) were 
purchased from Tocris Cookson (Ellisville, MO, U.S.A.). RS-127445 (selective 5-HT2B 
receptor antagonist), ondansetron (selective 5-HT3 receptor antagonist) and SB-203186 
(selective 5-HT4 receptor antagonist) were synthesized at Pfizer Inc. All the drugs, 
except for L-NOARG, RS-127445 and ondansetron, were dissolved in distilled water to 
produce 10-2 or 10-3 M and then diluted to the required concentrations with 
Krebs-Ringer solution. L-NOARG was dissolved in Krebs-Ringer solution to produce 
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10-2 M. RS-127445 was dissolved in dimethyl sulfoxide to produce 10-3 M and then 
diluted to the required concentrations with distilled water. Ondansetron was dissolved in 
40% sulfobutylether-β-cyclodextrin to produce 10-2 M and then diluted to the required 
concentrations with distilled water. 
 
Statistics 
Data were presented as mean ± S.E.M. The comparison between the control group 
and the antagonist-treated group was carried out by unpaired t-test with Welch's 
correction. P values of less than 0.05 were regarded as significant. 
 
3. Results 
 
Effect of exogenous 5-HT on the antral, corporal and fundic circular muscle. 
The strips from gastric antrum and corpus displayed spontaneous phasic and cyclic 
activity, respectively. Conversely, the rat gastric fundic circular muscle strips did not 
show spontaneous activity. 5-HT evoked both tonic and phasic contractile activity in 
gastric antral strips and tonic contractile activities in gastric corporal and fundic strips 
(Fig. 27). 5-HT evoked concentration-dependent contraction of strips from antrum 
(5-HT at 10-8 to 3 x 10-4 M), corpus (5-HT at 10-8 to 3 x 10-4 M) and fundus (5-HT at 
10-10 to 3 x 10-6 M) (Fig. 28). EC50 values for 5-HT were 1.97 x 10-5 M in the antrum, 
8.22 x 10-6 M in the corpus and 4.64 x 10-8 M in the fundus. 
The contractile responses of the antral strips to 5-HT were potentiated by pretreatment 
with tetrodotoxin (TTX, 10-6 M) and tended to be inhibited by pretreatment with 
atropine (10-6 M). However the inhibitory effect of atropine was not statistically 
significant. The contractions of the corporal and fundic strips to 5-HT were not affected 
by pretreatment with either TTX (10-6 M) or atropine (10-6 M) (Figs. 29, 30). The 
contractile responses of the antral strips to 5-HT were potentiated by pretreatment with 
Nω-Nitro-L-arginine (L-NOARG, 10-4 M) (Fig. 31). 
 
Effects of 5-HT receptor antagonists on the 5-HT-induced contractions of the antral 
circular muscle. 
Pretreatment with WAY-100635 (10-6 M), GR127935 (10-7 M), ketanserin (10-7 and 
10-6 M), RS-127445 (10-7 M), ondansetron (10-6 M) and SB-269970 (10-6 M) had no 
effect on the 5-HT-induced contractions of the antral strips (Fig. 32A, B, D, E, F and H). 
Pretreatment with methysergide (10-7 M) inhibited the 5-HT-induced contractions of the 
antral strips (Fig. 32C). The inhibitory effect of ketanserin was not significant, but at 
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10-6 M ketanserin tended to attenuate the contractile responses (Fig. 32D). Pretreatment 
with SB-203186 (10-6 M) enhanced the 5-HT-induced contractions of the antral strips 
(Fig. 32G). 
 
Effects of 5-HT receptor antagonists on the 5-HT-induced contractions of the corporal 
circular muscle. 
Pretreatment with WAY-100635 (10-6 M), GR127935 (10-7 M), RS-127445 (10-7 M), 
ondansetron (10-6 M), SB-203186 (10-6 M) and SB-269970 (10-6 M) had no effect on 
the 5-HT-induced contractions of the corporal strips (Fig. 33A, B, E, F, G and H). 
Pretreatment with methysergide (10-7 M) and ketanserin (10-7 and 10-6 M) inhibited the 
5-HT-induced contractions of the corporal strips (Fig. 33C and D). 
 
Effects of 5-HT receptor antagonists on the 5-HT-induced contractions of the fundic 
circular muscle. 
Pretreatment with WAY-100635 (10-6 M), GR127935 (10-7 M), ketanserin (10-7 and 
10-6 M), ondansetron (10-6 M) and SB-269970 (10-6 M) had no effect on the 
5-HT-induced contractions of the fundic strips (Fig. 34A, B, D, F and H). The effect of 
ketanserin at 10-7 M was not significant, but showed a tendency to enhance the 
contractile response to 5-HT (Fig. 34D). Pretreatment with cinanserin (10-6 M) 
enhanced the 5-HT-induced contractions of the fundic strips (Fig. 35). Pretreatment with 
SB-203186 (10-6 M) also enhanced the 5-HT-induced contractions of the fundic strips 
(Fig. 34G). Pretreatment with methysergide (10-7 M) and RS-127445 (10-7 M) inhibited 
the 5-HT-induced contractions of the fundic strips (Fig. 34C and E). 
 
 
 - 48 -
 
 
 
 
 
 (A) Antrum
(B) Corpus
(C) Fundus
1 g
1 g
2 g
2 min
5-HT 3x10-7 M 3x10-6 M 3x10-5 M 3x10-4 M
5-HT 3x10-7 M 3x10-6 M 3x10-5 M 3x10-4 M
5-HT 3x10-9 M 3x10-8 M 3x10-7 M 3x10-6 M
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 27. Trace showing typical effect of 5-HT on the strips from antrum (A), 
corpus (B), and fundus (C) of the rat stomach.  - 49 -
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 Figure 28. Concentration-response curves for 5-hydroxytryptamine (5-HT) of the
strips from antrum (A), corpus (B), and fundus (C) of the rat stomach. The
contractions induced by 5-HT was represented as their amplitude relative to
amplitude of the contraction induced by 10-5 M carbachol. Each point represents the 
mean ± S.E.M. from 5 animals.  - 50 -
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 Figure 29. Effects of atropine on 5-HT-induced contractions of the strips from 
antrum (A), corpus (B), and fundus (C) of the rat stomach. Atropine was applied 10 
min before addition of 5-HT. The contractions induced by 5-HT was represented as 
their amplitude relative to amplitude of the contraction induced by 10-5 M carbachol.
Each point represents the mean ± S.E.M. from 7-10 animals.  - 51 -
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 Figure 30. Effects of tetrodotoxin (TTX) on 5-HT-induced contractions of the strips 
from antrum (A), corpus (B), and fundus (C) of the rat stomach. TTX was applied 10
min before addition of 5-HT. The contractions induced by 5-HT was represented as 
their amplitude relative to amplitude of the contraction induced by 10-5 M carbachol.
Each point represents the mean ± S.E.M. from 7-10 animals. *: P<0.05, **: 
P<0.01, compared with the value in the absence of TTX (unpaired t-test with 
Welch’s correction).  - 52 -
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 Figure 31. Effect of Nω-Nitro-L-arginine (L-NOARG) on 5-HT-induced
contractions of the strips from corpus of the rat stomach. L-NOARG was
applied 10 min before addition of 5-HT. The contractions induced by 5-HT
was represented as their amplitude relative to amplitude of the contraction
induced by 10-5 M carbachol. Each point represents the mean ± S.E.M.
from 6 animals. **: P<0.01, compared with the value in the absence of
antagonists (unpaired t-test with Welch’s correction).  - 53 -
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 Figure 32. Effects of 5-HT receptor antagonists on 5-HT-induced contractions of the
strips from antrum of the rat stomach. WAY-100635 (A), GR127935 (B),
methysergide (C), ketanserin (D), RS-127445 (E), ondansetron (F), SB-203186 (G)
or SB-269970 (H) was applied 10 min before addition of 5-HT.  The contractions
induced by 5-HT was represented as their amplitude relative to amplitude of the
contraction induced by 10-5 M carbachol. Each point represents the mean ± S.E.M.
from 7-9 animals. *: P<0.05, **: P<0.01, compared with the value in the absence of
antagonists (unpaired t-test with Welch’s correction).  - 54 -
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 Figure 33. Effects of 5-HT receptor antagonists on 5-HT-induced contractions of the
strips from corpus of the rat stomach. WAY-100635 (A), GR127935 (B),
methysergide (C), ketanserin (D), RS-127445 (E), ondansetron (F), SB-203186 (G)
or SB-269970 (H) was applied 10 min before addition of 5-HT.  The contractions
induced by 5-HT was represented as their amplitude relative to amplitude of the
contraction induced by 10-5 M carbachol. Each point represents the mean ± S.E.M.
from 7-9 animals. *: P<0.05, **: P<0.01, compared with the value in the absence of
antagonists (unpaired t-test with Welch’s correction).  - 55 -
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 Figure 34. Effects of 5-HT receptor antagonists on 5-HT-induced contractions of the 
strips from corpus of the rat stomach. WAY-100635 (A), GR127935 (B), 
methysergide (C), ketanserin (D), RS-127445 (E), ondansetron (F), SB-203186 (G) 
or SB-269970 (H) was applied 10 min before addition of 5-HT.  The contractions 
induced by 5-HT was represented as their amplitude relative to amplitude of the 
contraction induced by 10-5 M carbachol. Each point represents the mean ± S.E.M. 
from 7-10 animals. *: P<0.05, **: P<0.01, compared with the value in the absence 
of antagonists (unpaired t-test with Welch’s correction).  - 56 -
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 Figure 35. Effect of cinanserin on 5-HT-induced contractions of the strips
from corpus of the rat stomach. Cinanserin was applied 10 min before
addition of 5-HT. The contractions induced by 5-HT was represented as their
amplitude relative to amplitude of the contraction induced by 10-5 M
carbachol. Each point represents the mean ± S.E.M. from 8-10 animals. *:
P<0.05, compared with the value in the absence of antagonists (unpaired
t-test with Welch’s correction).  - 57 -
4. Discussion 
 
Exogenously applied 5-HT caused contractions of the circular muscle strips from the 
rat gastric antrum, corpus and fundus. The fundic strips showed higher sensitivity to 
5-HT than those of antrum and corpus. Similar results were reported in the circular 
muscle rings from the mouse stomach (86). The fundus showed higher sensitivity to 
5-HT than the antrum. Regional differences of 5-HT receptor distribution might cause 
the observed regional sensitivity differences. The contractile responses of the antral 
strips to 5-HT at concentrations of less than 3x10-6 M were enhanced by TTX. Atropine 
tended to inhibit gastric antral contractions at low concentrations of 5-HT, although this 
did not reach statistical significance. From these results, in rat gastric antral circular 
muscle, contractile responses to low concentrations of 5-HT could be mediated through 
postganglionic cholinergic neurons and regulated by inhibitory neurons. On the other 
hand, antral contractions to high concentrations of 5-HT were not blocked by atropine 
nor TTX, indicating the participation of 5-HT receptors directly located on circular 
smooth muscle. Furthermore, contractile responses to 5-HT in the corporal and fundic 
strips were also resistant to both atropine and TTX. Based on these results it is likely 
that corporal and fundic contractions to exogenous 5-HT were mediated via 5-HT 
receptors located directly on the circular smooth muscle. The regional and functional 
differences of 5-HT in circular muscle strips from guinea pig stomach have been studied 
(80, 81). In guinea pigs, 5-HT evoked contractile responses in the antrum and fundus, 
whilst relaxant responses in the corpus. According to these reports, antral contractions 
were mediated through neuronal stimulation alone (80) or a combination of both 
neuronal and smooth muscle stimulations (81). TTX inhibited contractile responses to 
5-HT in the guinea pig antrum (80, 81), suggesting the existence of different neuronal 
mechanisms between rats and guinea pigs. In the rat colon, TTX enhanced circular 
muscle contractions (87), indicating the attribution of inhibitory neurons such as nitric 
oxide (NO)-releasing neuron (87, 88) and vasoactive intestinal polypeptide 
(VIP)-containing neuron (87). In this chapter, a NO synthetase inhibitor, L-NOARG 
enhanced contractile responses to 5-HT, suggesting NO-releasing inhibitory neurons 
may be involved and dominant in the rat antrum. On the other hand, the excitatory 
neurons are dominant in the guinea pig antrum. Furthermore, in guinea pigs, the effects 
of 5-HT on the corpus and fundus were attributed to stimulation of 5-HT receptors on 
the smooth muscle. The suggested mechanisms of 5-HT on the corpus and fundus are 
similar in both rats and guinea pigs, although functions observed in the corpus are 
different. 
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In the antrum, the 5-HT-induced contractions were significantly inhibited by 
methysergide (5-HT1, 5-HT2, 5-ht5, 5-HT6 and 5-HT7 receptor antagonist), however 
contractions were not inhibited by either WAY-100635 (selective 5-HT1A receptor 
antagonist), GR127935 (5-HT1B/1D receptor antagonist) or SB-269970 (selective 5-HT7 
receptor antagonist), suggesting the involvement of 5-HT2, 5-ht5 and 5-HT6 receptors. 
The pKi values of methysergide to rat 5-ht5 and 5-HT6 receptors were reported to be 
smaller than 7 (89-91), therefore an inhibitory effect at 5-ht5 and 5-HT6 receptors by 
methysergide at 10-7 M is unlikely. RS-127445 (selective 5-HT2B receptor antagonist) 
slightly inhibited and 10-6 M ketanserin (non-selective 5-HT2 receptor antagonist) 
tended to inhibit the antral contractile responses to 5-HT, although these effects were 
not statistically significant. Furthermore, distribution of 5-HT2C receptors has been 
limited to the CNS and choroid plexus (71). These results suggested that 5-HT-induced 
contractions of the gastric antral circular muscles were mediated through 5-HT2A and 
5-HT2B receptors. Consistent with this result, the involvement of 5-HT2 receptors in 
gastric antral muscle contractions induced by 5-HT was reported in guinea pigs (80, 81) 
and mice (86). In addition, Takemura et al. (81) reported the involvement of 5-HT3 and 
5-HT4 receptors on contractile responses and 5-HT1 receptors on relaxant responses in 
the guinea pig antrum, and James et al. (86) reported the involvement of 5-HT4 
receptors on contractile responses in the mouse antrum. Contradictory to these reports, 
in this chapter, 5-HT-induced contractions were significantly enhanced by SB-203186 
(selective 5-HT4 receptor antagonist), suggesting the involvement of 5-HT4 receptors 
for antral relaxations. This discrepancy was also demonstrated between the ileum strips 
from guinea pigs (24) and rats (92, 93). In the rat ileum, 5-HT4 receptors are located on 
the smooth muscles and promote cAMP formation (71), resulting in the relaxation. Our 
results are consistent with earlier findings that a selective 5-HT4 receptor antagonist, SB 
204070 tended to enhance the contractions to 5-HT in the rat ileum (93).
In the corpus, the contractile responses to 5-HT were significantly inhibited by 
methysergide and ketanserin. However contractions were not inhibited by WAY-100635, 
GR127935, RS-127445 or SB-269970, suggesting the involvement of 5-HT2A receptors 
in the contraction. The effect of 5-HT on rat corporal strips remains to be fully 
investigated. However, platelet-activating factor (PAF)-induced corporal contractions 
were blocked by methysergide, indicating the involvement of 5-HT in the rat corporal 
contraction (94). Janssen et al. (95, 96) have shown the mediation of contractions in 
canine and porcine proximal stomach longitudinal smooth muscles to involve 5-HT2A 
receptors, which is consistent with the present results. On the other hand, in guinea pig 
corpus, 5-HT caused relaxations that were mediated via 5-HT1 receptors (79-81). In this 
 - 59 -
chapter, pretreatment with WAY-100635 or GR127935 did not demonstrate apparent 
effect on 5-HT-induced contractions, but tended to enhance the contraction. It is 
probable that 5-HT1 receptors cause relaxations in the rat corpus, but its functional 
contribution on these responses to 5-HT is limited. Ondansetron also tended to enhance 
the 5-HT-induced contractions, implying that 5-HT3 receptors cause relaxations in the 
rat corpus. 
In the fundus, the 5-HT-evoked contractions were significantly inhibited by 
methysergide and RS-127445, but were not antagonized by WAY-100635, GR127935 or 
ketanserin, suggesting the involvement of 5-HT2B receptors for the contraction. 5-HT2B 
receptors were first identified in rat stomach fundus (97, 98), and it is generally 
accepted that 5-HT2B receptors mediate rat fundic longitudinal smooth muscle 
contractions (67-69, 99). We have confirmed that 5-HT caused contractions through 
5-HT2B receptors not only in longitudinal strips but also in circular ones. Furthermore, 
10-7 M ketanserin tended to enhance contractile responses to 5-HT, but 10-6 M 
ketanserin did not influence the contraction. The pA2 value of ketanserin at 5-HT2B 
receptors in rat gastric fundic longitudinal muscles is less than 6.0 (99) and the pKB 
values of ketanserin at human 5-HT2A and 5-HT2B receptors expressed cells are 8.7 and 
6.0, respectively (100). It is likely that 5-HT2B receptors antagonism of 10-6 M 
ketanserin could counteract the enhancement of 5-HT-induced contraction via its 
5-HT2A receptors antagonism. In order to confirm the involvement of 5-HT2A receptors 
in 5-HT-induced fundic relaxations, cinanserin, which is a selective 5-HT2 receptor 
antagonist showing low affinity to 5-HT2B binding sites (9) was applied. Application of 
10-6 M cinanserin significantly enhanced contractile responses to 5-HT, indicating the 
presence of 5-HT2A receptor-mediated relaxations in this tissue. In addition, SB-203186 
also increased 5-HT-caused fundic contractions, suggesting the involvement of 5-HT4 
receptors for the relaxations. Amemiya et al. (68) reported that 5-HT4 receptors 
mediated contractions in the rat fundus. The conflicting results could at least in part be 
due to the differences in smooth muscle preparations between circular muscles and 
longitudinal ones. In the earlier findings, 5-methoxytryptamine induced the rat fundic 
contractions of the longitudinal strips, and these responses were antagonized by atropine, 
TTX and SDZ 205-557 (5-HT4 receptor antagonist). These results suggested that the 
longitudinal muscle contractions were mediated through 5-HT4 receptors located on 
cholinergic neurons. This contractile mechanism is similar to the case of an 
enhancement of electrically-evoked contractions by 5-HT4 agonists. On the other hand, 
the present study suggested that the fundic circular muscle relaxations were mediated 
through 5-HT4 receptors located on smooth muscle. Similar results are reported in the 
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rat ileum (92) and the rat esophagus (37, 101). In the tunica muscularis mucosae of the 
rat esophagus, 5-HT4 receptors stimulated cAMP formation results in the relaxation 
(101). Similar to 5-HT4 receptors, 5-HT7 receptors coupled to Gs protein activate cAMP 
formation and are expressed in the rat fundus (102), supporting the fundic relaxation via 
5-HT7 receptors. In the present study, SB-269970 tended to enhance the 5-HT-induced 
fundic contractions. It is probable that a relaxation pathway involving 5-HT7 receptors 
is present in the rat fundus. 
In Chapter II, effects of 5-HT-related compounds had been investigated using in vivo 
rat gastric emptying and gastric motility models. A 5-HT2 receptor agonist, 
α-methyl-5-HT stimulated gastric motility. The contractile 5-HT2A and 5-HT2B 
receptors identified in antral, corporal and fundic circular muscles may play a role in the 
in vivo contractile activities. The gastrokinetic effect of 5-HT4 agonists also 
demonstrated in rats. In this chapter, the relaxant 5-HT4 receptors were identified in 
antral and fundic circular muscles. In the rat stomach, 5-HT4 receptors located on 
cholinergic neurons may increase acetylcholine release that enhances the contractions 
similar as in guinea pigs (25). Thus, this contractile mechanism may dominantly occur, 
though the circular muscle relaxation is also observed. Furthermore, ondansetron 
accelerated gastric empting but did not change gastric antral motility. Ondansetron 
tended to enhance contractile responses to 5-HT in the corpus. This enhanced 
contraction may play a role in part to accelerate gastric emptying.  
In conclusion, the main finding of this chapter is that 5-HT mediates contractile 
responses in rat stomach circular muscle through multiple 5-HT receptor subtypes. 
5-HT induces contractions of the circular muscle strips from all three gastric regions. 
The sensitivity to 5-HT of the fundus is higher than those of antrum and corpus. 
Contractile responses to 5-HT in the antrum are mediated by 5-HT receptors on smooth 
muscle and neurons and in the corpus and fundus are mainly mediated by 5-HT 
receptors located directly on smooth muscle. At least three receptor subtypes mediate 
the contractile responses observed in rat stomach circular muscles. The contractile 
5-HT2A and 5-HT2B receptors and the relaxant 5-HT4 receptors in the antrum, the 
contractile 5-HT2A receptors in the corpus, and the contractile 5-HT2B receptors and the 
relaxant 5-HT2A and 5-HT4 receptors in the fundus may be present. The regional 
difference of expressed 5-HT receptor subtypes and the contractile responses and 
affinities to 5-HT might cause the regional difference of the sensitivity and the efficacy 
to 5-HT. This chapter has clarified that contractile responses to 5-HT present regional 
and functional differences in rat stomach circular muscle, which are species-specific. 
The regional differences of the sensitivity to 5-HT may be regulated by several 5-HT 
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receptor subtypes which modulate gastric emptying in a cooperative way in rats. 
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Chapter IV: Effects of 5-HT4 receptor agonists on contractile responses of circular 
muscle from the rat stomach 
 
1. Introduction 
 
As shown in Chapter III, regional and functional differences to 5-HT in rat gastric 
circular muscles are characterized. In the antrum, the contractile responses to 5-HT are 
mediated by 5-HT receptors on both smooth muscle and neurons. 5-HT induces 
contractions via 5-HT2A and 5-HT2B receptors and relaxations via 5-HT4 receptors. In 
the corpus, 5-HT induces contractions via 5-HT2A receptors on smooth muscle. In the 
fundus, the contractile responses to 5-HT are mediated by 5-HT receptors on smooth 
muscle. 5-HT induces contractions via 5-HT2B receptors and relaxations via 5-HT2A and 
5-HT4 receptors. 
Other than 5-HT4 agonism, it is reported that cisapride enhanced acetylcholine release 
from guinea pig ileum due to the blockade of 5-HT1 receptors, but inhibited 
acetylcholine release from guinea pig ileum due to the blockade of 5-HT3 receptors (25). 
5-HT2A antagonism of cisapride was suggested in longitudinal muscles from the rat 
ileum (93) and canine colon (103). With regard to tegaserod, 5-HT2B receptor 
antagonistic activity was reported in rat fundic strips (39). Other than these reports, 
pharmacological characterization of cisapride, mosapride and tegaserod to 5-HT 
receptor subtypes are limited. 
In this chapter, in order to differentiate pharmacological profiles among the 5-HT4 
agonists, effects of cisapride, mosapride, tegaserod and CJ-033466 on rat gastric 
circular muscle of the antrum, corpus and fundus were investigated. 
 
2. Materials and Methods 
 
Methods for preparation of smooth muscle strips from the rat stomach and 
measurement of mechanical activity are as same as Chapter III. Briefly, Single doses of 
agonists were applied and then washed out on an interval of 30 to 35 min. To evaluate 
the effects of 5-HT4 agonists on 5-HT-induced contractions or the effects of SB-203186 
on 5-HT4 agonist-induced contractile responses, the tissue strips were exposed to the 
5-HT4 agonists or SB-203186 10 min before and during application of 5-HT or the 
5-HT4 agonist, respectively. To evaluate the effects of 5-HT4 agonists on 
α-methyl-5-HT-induced contractions, the tissue strips were exposed to ketanserin (10-7 
M) or RS-127445 (10-7 M) 12 min before and 5-HT4 agonists 10 min before and during 
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application of α-methyl-5-HT. Amplitudes of contraction and relaxation are represented 
relative to amplitude of contraction elicited by 10-5 M carbachol. 
 
Chemicals 
CCh was purchased from Wako Pure Chemicals (Osaka, Japan). 5-HT, 
α-methyl-5-HT maleate and ketanserin tartrate were purchased from Sigma (St. Louis, 
MO, U.S.A.). CJ-033466, cisapride, mosapride, tegaserod, SB-203186 and RS-127445 
were synthesized at Pfizer Inc. 
CCh, 5-HT, α-methyl-5-HT and ketanserin were dissolved in distilled water to 
produce 10-2 or 10-3 M and then diluted to the required concentrations with 
Krebs-Ringer solution. RS-127445 was dissolved in dimethyl sulfoxide to produce 10-3 
M and then diluted to the required concentrations with distilled water. For 
concentration-response curve study, mosapride and tegaserod were dissolved in 40% 
sulfobutylether-β-cyclodextrin (SBECD) to produce 10-2 M and diluted to 10-3 M with 
distilled water and then diluted to the required concentrations with Krebs-Ringer 
solution. Cisapride and CJ-033466 were dissolved in 1% lactic acid to produce 10-2 M 
and diluted to 10-3 M with distilled water and then diluted to the required concentrations 
with Krebs-Ringer solution. For examining the effect on contractile responses to 5-HT 
and α-methyl-5-HT, mosapride and tegaserod were dissolved in 40% SBECD to 
produce 10-2 M and diluted to 10-3 M with 4% SBECD. Cisapride and CJ-033466 were 
dissolved in 1% lactic acid to produce 10-2 M and then diluted to the required 
concentrations with 1% lactic acid. 
 
Statistics 
Data were presented as mean ± S.E.M. The comparison between the control group 
and the antagonist-treated group was carried out by unpaired t-test with Welch's 
correction. P values of less than 0.05 were regarded as significant. 
 
3. Results 
 
Effects of 5-HT4 receptor agonists on the antral, corporal and fundic circular muscle. 
  Cisapride evoked contractions in gastric antral strips at 3x10-6 M to 3x10-5 M. The 
maximal response was observed at a concentration of 10-5 M. Cisapride did not induce 
marked responses in the corpus and fundus (Fig. 36). Mosapride relaxed gastric 
corporal strips at concentrations higher than 10-5 M, but did not induce marked 
responses in gastric antral and fundic strips (Fig. 37). Tegaserod evoked marked 
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contractions in gastric antral, corporal and fundic strips at a concentration of 10-4 M (Fig. 
38). CJ-033466 evoked contractions in gastric corporal strips at the concentration of 
10-4 M. CJ-033466 did not induce marked responses in the antrum, but tended to relax 
in the fundus (Fig. 39). 
 
Effects of SB-203186 on the 5-HT4 receptor agonists-induced contractile responses. 
  Pretreatment of SB-203186 (10-6 M) did not block the cisapride (10-5 M)-evoked 
contraction in the antrum, mosapride (10-4 M)-induced relaxation in the corpus, 
tegaserod (10-4 M)-evoked contractions in the fundus or CJ-033466 (10-4 M)-evoked 
contractions in the corpus (Fig. 40). 
 
Effects of 5-HT4 receptor agonists on the 5-HT-induced contractions of the antral, 
corporal and fundic circular muscle. 
  Pretreatment with cisapride (10-6 M) tended to inhibit contractile responses to 5-HT 
(3 x 10-6 M), whilst enhanced contractile responses to 5-HT (3 x 10-4 M) of the antral 
strips. Cisapride inhibited 5-HT-induced contractions of the corporal and fundic strips 
(Fig. 41). Pretreatment with mosapride (10-6 M) inhibited 5-HT-induced contractions of 
the fundic strips. Mosapride tended to inhibit 5-HT-induced contractions of the antral 
strips, but the inhibitory effect was not statistically significant. Mosapride had no effect 
on the 5-HT-induced contractions of the corporal strips (Fig. 42). Pretreatment of 
tegaserod (10-6 M) inhibited 5-HT-induced contractions of the fundic strips. Tegaserod 
tended to inhibit 5-HT-induced contractions of the antral strips, but the inhibitory effect 
was not statistically significant. Tegaserod had no effect on the 5-HT-induced 
contractions of the corporal strips (Fig. 43). Pretreatment of CJ-033466 (10-8 and 10-6 
M) had no effect on the 5-HT-induced contractions of the antral, corporal and fundic 
strips (Fig. 44). 
 
Effects of 5-HT4 receptor agonists on the α-methyl-5-HT-induced contractions of the 
antral, corporal and fundic circular muscle. 
  Alpha-methyl-5-HT evoked concentration-dependent contraction of the strips from 
antrum, corpus and fundus (Figs 45, 46). Cisapride (10-6 M) inhibited 
α-methyl-5-HT-induced contractions of the corporal strips under the treatment with 
RS-127445 (Fig.45A). Cisapride (10-6 M), mosapride (10-6 M) or tegaserod (10-6 M) 
inhibited α-methyl-5-HT-induced contractions of the fundic strips under the treatment 
with ketanserin (Fig. 45B - D). In the antral strips, cisapride had no effect on 
α-methyl-5-HT-induced contractions under the treatment with RS-127445, but tended to 
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inhibit that under the treatment with ketanserin (Fig. 46A, B). Mosapride tended to 
enhance α-methyl-5-HT-induced contractions under the treatment with ketanserin, but 
one of 6 strips exhibited strong contractions. Except for it, concentration-response 
curves for α-methyl-5-HT in the absence of mosapride was comparable with that in the 
presence of mosapride (Fig. 46C). Tegaserod had no effect on α-methyl-5-HT-induced 
contractions under the treatment with ketanserin (Fig. 46D).  
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 Figure 36. Concentration-response curves for cisapride of the strips from antrum
(A), corpus (B), and fundus (C) of the rat stomach. The contractions induced by 
cisapride was represented as their amplitude relative to amplitude of the contraction
induced by 10-5 M carbachol. Each point represents the mean ± S.E.M. from 5 
animals.  - 67 -
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 Figure 37. Concentration-response curves for mosapride of the strips from antrum
(A), corpus (B), and fundus (C) of the rat stomach. The contractions induced by 
mosapride was represented as their amplitude relative to amplitude of the
contraction induced by 10-5 M carbachol. Each point represents the mean ± S.E.M. 
from 5 animals.  - 68 -
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 Figure 38. Concentration-response curves for tegaserod of the strips from antrum 
(A), corpus (B), and fundus (C) of the rat stomach. The contractions induced by 
tegaserod was represented as their amplitude relative to amplitude of the contraction 
induced by 10-5 M carbachol. Each point represents the mean ± S.E.M. from 5 
animals.  - 69 -
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 Figure 39. Concentration-response curves for CJ-033466 of the strips from antrum 
(A), corpus (B), and fundus (C) of the rat stomach. The contractions induced by 
CJ-033466 was represented as their amplitude relative to amplitude of the
contraction induced by 10-5 M carbachol. Each point represents the mean ± S.E.M. 
from 5 animals.  - 70 -
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 Figure 40. Effects of SB-203186 on cisapride (10-5 M)-induced contractions in the 
antrum (A), mosapride (10-4 M)-induced relaxations in the corpus (B), tegaserod 
(10-4 M)-induced contractions in the fundus and CJ-033466 (10-4 M)-induced 
contractions in the corpus. SB-203186 (10-6 M) was applied 10 min before addition 
of 5-HT4 agonists.  The contractile responses induced by 5-HT4 agonists were 
represented as their amplitude relative to amplitude of the contraction induced by
10-5 M carbachol. Each point represents the mean ± S.E.M. from 3 to 5 animals.  - 71 -
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 Figure 41. Effects of cisapride on 5-HT-induced contractions of the strips from 
antrum (A), corpus (B), and fundus (C) of the rat stomach. Cisapride was applied 10 
min before addition of 5-HT.  The contractions induced by 5-HT was represented 
as their amplitude relative to amplitude of the contraction induced by 10-5 M 
carbachol. Each point represents the mean ± S.E.M. from 8 animals. *: P<0.05, 
**: P<0.01, compared with the value in the absence of cisapride (unpaired t-test with 
Welch’s correction).  - 72 -
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 Figure 42. Effects of mosapride on 5-HT-induced contractions of the strips from 
antrum (A), corpus (B), and fundus (C) of the rat stomach. Mosapride was applied 
10 min before addition of 5-HT.  The contractions induced by 5-HT was 
represented as their amplitude relative to amplitude of the contraction induced by
10-5 M carbachol. Each point represents the mean ± S.E.M. from 8 animals. *:
P<0.05, **: P<0.01, compared with the value in the absence of mosapride (unpaired 
t-test with Welch’s correction).  - 73 -
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 Figure 43. Effects of tegaserod on 5-HT-induced contractions of the strips from 
antrum (A), corpus (B), and fundus (C) of the rat stomach. Tegaserod was applied 10 
min before addition of 5-HT.  The contractions induced by 5-HT was represented 
as their amplitude relative to amplitude of the contraction induced by 10-5 M 
carbachol. Each point represents the mean ± S.E.M. from 8 animals. *: P<0.05, 
**: P<0.01, compared with the value in the absence of tegaserod (unpaired t-test 
with Welch’s correction).  - 74 -
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 Figure 44. Effects of CJ-033466 on 5-HT-induced contractions of the strips from 
antrum (A), corpus (B), and fundus (C) of the rat stomach. CJ-033466 was applied 
10 min before addition of 5-HT.  The contractions induced by 5-HT was 
represented as their amplitude relative to amplitude of the contraction induced by
10-5 M carbachol. Each point represents the mean ± S.E.M. from 8 animals.  - 75 -
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 Figure 45. Effects of 5-HT4 agonists on α-methyl-5-HT-induced contractions of the
strips from corpus (A) and fundus (B - D) of the rat stomach. Cisapride (A, B), 
mosapride (C) or tegaserod (D) was applied 10 min before addition of 
α-methyl-5-HT. RS-127445 (10-7 M) for the corpus or ketanserin (10-7 M) for the 
fundus was applied 12 min before addition of α-methyl-5-HT. The contractions
induced by α-methyl-5-HT was represented as their amplitude relative to amplitude
of the contraction induced by 10-5 M carbachol. Each point represents the mean ± 
S.E.M. from 6 animals. *: P<0.05, **: P<0.01, compared with the value in the 
absence of 5-HT4 agonists (unpaired t-test with Welch’s correction).  - 76 -
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 Figure 46. Effects of 5-HT4 agonists on α-methyl-5-HT-induced contractions of the
strips from antrum of the rat stomach. Cisapride (A, B), mosapride (C) or tegaserod 
(D) was applied 10 min before addition of α-methyl-5-HT. RS-127445 (10-7 M, A) 
or ketanserin (10-7 M, B - D) was applied 12 min before addition of α-methyl-5-HT. 
The contractions induced by α-methyl-5-HT was represented as their amplitude
relative to amplitude of the contraction induced by 10-5 M carbachol. Each point 
represents the mean ± S.E.M. from 6 animals.  - 77 -
4. Discussion 
 
Pretreatment of SB-203186 (10-6 M) did not block the cisapride (10-5 M)-evoked 
contractions in the antrum, mosapride (10-4 M)-induced relaxations in the corpus, 
tegaserod (10-4 M)-evoked contractions in the fundus, nor CJ-033466 (10-4 M)-evoked 
contractions in the corpus, suggesting these observed effects were induced via other 
than 5-HT4 receptors. Cisapride is known to stimulate spontaneous motility of isolated 
ileum and gastroduodenum preparations from the guinea pig (25, 104). Taniyama et al. 
(25) suggested that at high concentrations of cisapride (10-6 M to 10-5 M)-evoked ileal 
contractions and the release of acetylcholine were induced via putative 5-HT4 receptors. 
In the present study, SB-203186 did not block cisapride-evoked spontaneous contraction 
in the rat antrum. The conflicting results could at least in part be due to the differences 
in tissue preparations between the guinea pig ileum and the rat antrum. Furthermore, 
cisapride is a fairly potent HERG K+ channel blocker (105, 106). It is known that 
HERG K+ channel are expressed on intestinal cells of Cajal which regulates 
gastrointestinal motor activity (107, 108). The blockade of HERG K+ channel by 
cisapride may stimulate contractile activities in the antrum. This mechanism also may 
play a role in the enhancement of 3 x 10-4 M 5-HT-induced contractions by cisapride. 
Tegaserod (10-4 M) evoked contractions in all the regions, indicating that non-specific 
mechanisms such as Ca2+ influx may be involved. The relaxant responses to mosapride 
and contractile responses to CJ-033466 were regional-specific, but pathways that induce 
these responses still remain unclear. 
In the fundus, cisapride, mosapride and tegaserod inhibited contractile responses to 
5-HT. 5-HT2B antagonism blocked 5-HT-induced fundic contractions (Fig. 34). 
Cisapride, mosapride and tegaserod also inhibited contractile responses to 
α-methyl-5-HT, a 5-HT2 agonist under the treatment with 10-7 M ketanserin which 
selectively blocked 5-HT2A receptor. These results suggested that not only tegaserod but 
also cisapride and mosapride may have 5-HT2B receptor antagonistic activities. In rat 
gastric emptying study, it is suggested that 5-HT2B antagonism of tegaserod may 
contribute the lack of efficacy on gastric emptying. A high potency of tegaserod to the 
5-HT2B receptor may affect on the gastric emptying. 
In the corpus, cisapride inhibited 5-HT-induced contractions as similar as those of 
5-HT2A receptor antagonists as shown in Fig. 33. Cisapride also inhibited contractile 
responses to α-methyl-5-HT under the treatment with 10-7 M RS-127445 which 
selectively blocked 5-HT2B receptor, indicating that cisapride has 5-HT2A antagonism.  
In the antrum, cisapride tended to inhibit 3 x 10-6 M 5-HT-induced contractions. 
 - 78 -
Mosapride and tegaserod also tended to inhibit 5-HT-induced contractions. These 
inhibitory effects were not significant statistically, but similar tendency was observed by 
pretreatment with RS-127445 against 5-HT-induced contractions (Fig. 32), suggesting 
the involvement of 5-HT2B antagonism of these compounds. On the other hand, 
contractile responses to α-methyl-5-HT were not inhibited by mosapride and tegaserod 
under the treatment with ketanserin. From these results, the involvement with 5-HT2B 
receptor to 5-HT-induced contractions in the antrum may be limited. Cisapride had no 
effect on α-methyl-5-HT under the treatment with RS-127445, but tended to inhibit 
α-methyl-5-HT under the treatment with ketanserin. The results from the fundus and 
corpus, cisapride has both 5-HT2A and 5-HT2B receptor antagonistic activities. 
Furthermore, a high concentration of ketanserin (10-6 M) demonstrated the tendency to 
inhibit 5-HT-induced contractions (Fig. 32). These results suggested that high 
concentration of 5-HT2A receptor antagonists is needed to inhibit contractile responses 
to 5-HT in the antrum. Thus, 5-HT-induced contractions in the antrum may be 
dominantly regulated by 5-HT2A receptors than 5-HT2B receptors. 
CJ-033466 had no effects on 5-HT-induced contractions in the antrum, corpus and 
fundus. Differently from cisapride, mosapride and tegaserod, CJ-033466 seems not to 
have 5-HT2A and 5-HT2B receptor antagonist activities. It is suggested that CJ-033466 
may have higher selectivity to 5-HT4 receptors. 
 
 
 - 79 -
Chapter V: Effects of CJ-033466 on ACh release from human gastric antral tissues 
 
1. Introduction 
 
  Stimulation of 5-HT4 receptors accelerates the motility of the gastrointestinal tract in 
vivo, while this stimulation shows excitatory or inhibitory effects on isolated 
preparations, depending on the species and anatomical region investigated (109, 110). In 
the isolated human colonic preparations, simulation of 5-HT4 receptors causes 
relaxations of circular muscles (111). In isolated preparations from rats, simulation of 
5-HT4 receptors causes relaxations of esophagus and ileum (37, 111), as is the case in 
human colonic tissue. On the other hand, in the isolated preparations of stomach (82, 
112), ileum (24, 25, 113) and colon (114) from guinea pigs, simulation of 5-HT4 
receptors causes contractions due to stimulation of excitatory neurons, such as 
cholinergic neurons and tachykinin-containing neurons.  
In vitro receptor autoradiography of 5-HT4 receptors in the human gastric antrum has 
demonstrated the localization of 5-HT4 receptors at the myenteric plexus of human 
gastric antrum (115). In this chapter, the function of 5-HT4 receptor in the human gastric 
antrum, in relation to the contractility and acetylcholine (ACh) release were examined. 
Furthermore, gastrokinetic effects of CJ-033466 have been evaluated as a 5-HT4 
agonist comparison with cisapride, mosapride and tegaserod in animal models. In vitro, 
other than 5-HT4 agonism, CJ-033466 demonstrates the different pharmacological 
profile from cisapride, mosapride and tegaserod. Therefore, in order to determine 
whether the action of CJ-033466 can be applied to human as a 5-HT4 agonist, effect of 
CJ-033466 on ACh release from human gastric antral tissues was examined. 
 
2. Materials and Methods 
 
Measurement of the mechanical activity  
Specimens of human gastric antrum were obtained from patients undergoing surgical 
resection for gastric cancer. The normal tissues adjacent to the pathological ones were 
cut and used. The mucosa was rapidly removed from the tissue. The strips were placed 
in a 20-mL organ bath in the presence of Krebs-Ringer solution of the following 
composition: 118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.19 mM MgSO4, 25.0 mM 
NaHCO3, 1.18 mM KH2PO4 and 11 mM glucose, oxygenated with 95% O2 and 5% CO2 
and maintained at 34-36℃. Approximately 1 g of resting tension were applied and were 
kept constant by re-adjustment during the equilibration period, and then the bath 
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medium was changed to Krebs-Ringer solution containing methysergide (10-7 M), 
ketanserin (10-7 M) and granisetron (10-7 M). Mechanical responses were recorded by 
means of an isometric transducer (SD-IT, Nihon Koden, Tokyo, Japan). The electrical 
field stimulation (EFS) was achieved using monophasic square-wave pulses of 4 msec 
pulse width and 5 Hz frequency at 70 V. EFS was applied for 20 s at 2 min intervals 10 
times for 30 min periods. After a stabilization of EFS-induced contraction, 5-HT was 
applied to the organ in the absence and presence of antagonists for 5-HT4 receptors. 
Atropine was applied to the same strips at the end of measurement of 5-HT effect. 
 
Measurement of [3H]ACh outflow 
Three preparations from the gastric antrum were incubated at 35℃ for 60 min with 
[3H]choline at a final concentration of 200 nM in Krebs solution. After washing in fresh 
Krebs solution for 15 min, the preparations were mounted in the superfusion apparatus 
and superfused at 1 mL/min with Krebs-Ringer solution gassed with 95% O2 and 5% 
CO2, maintained at 35-37℃. Experiments were begun 30 min after superfusion, and the 
superfusate was collected every 2 min 7 times (fractions) in a series. Two parallel 
platinum electrodes were used to stimulate intramural nerves. Electrical stimulation 
(ES) was applied to the preparation at the fourth fraction in a series, and successively 4 
times (S1, S2, S3 and S4) to the preparation at 30 min intervals. The conditions of ES 
were 1 msec pulse width, 3 Hz frequency at 60 V for 2 min. The superfusate was 
collected every 2 min and the radioactivity of the sample was determined by counting in 
a liquid scintillation spectrometer. The effect of ES was evaluated by the amounts of 
[3H]ACh outflow in the fourth fraction against the mean of those in 3 fractions before 
ES, the first to third fraction. Perfusion medium contained 10-7 M methysergide, 10-7 M 
ketanserin and 10-7 M granisetron to prevent the effect of 5-HT on the 5-HT1, 5-HT2 and 
5-HT3 receptors.  
The concentration-dependency of 5-HT was evaluated by comparing the ratio of 
S3/S2 and S4/S2 in three preparations isolated from the same specimen. In a preparation, 
5-HT was absent during S1, S2, S3 and S4 ES. In the other preparations, 5-HT was 
absent during S1 and S2 ES and present 2 min before and during the S3 and S4 ES. 
The effect of 5-HT4 receptor antagonist was also evaluated by comparing the ratio of 
S3/S2 and S4/S2 in three preparations isolated from the same specimen. In a preparation, 
5-HT was absent during S1, S2, S3 and S4 ES. In a preparation, 5-HT at 10-6 M was 
absent during S1 and S2 ES and present 2 min before and during the S3 and S4 ES. In 
another preparation, 5-HT at 10-6 M was absent during S1 and S2 ES and present 2 min 
before and during the S3 and S4 ES, and SB-203186 (5-HT4 receptor antagonist) at 10-6 
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M was present during S4 ES. 
CJ-033466 was applied the similar protocol as the 5-HT experiment, except for 
CJ-033466 was absent during S4 for the concentration-dependency experiment. 
CJ-033466 at 10-7 M was used for the antagonist experiment. 
 
Chemicals 
[3H]choline (3.33 TBq/mmol) was purchased from New England Nuclear (Boston, 
MA, USA). 5-HT creatinine sulfate was purchased from Sigma (St. Louis, MO, USA). 
Methysergide maleate and ketanserin tartrate were purchased from Research 
Biochemicals Int. (Natick, MA, USA). Atropine sulfate monohydrate and tetrodotoxin 
were purchased from Wako (Osaka, Japan). SB-203186 and granisetron were purchased 
from Tocris Cookson Inc (Ellisville, MO, USA). CJ-033466 was synthesized at Pfizer 
Inc. 
 
Statistics 
Data were presented as mean ± S.E.M. Data were analyzed by unpaired t-test. P 
values of less than 0.05 were regarded as significant. 
 
3. Results 
 
Effect of 5-HT on electrically stimulated contractions of human gastric antral 
preparations. 
  EFS (5 Hz, 4 msec) evoked a monophasic contraction over the spontaneous 
contractions in the antral preparations from the human stomach (Fig. 47A). Application 
of 10-6 M 5-HT enhanced EFS-induced gastric antral contractions (Fig. 47A). 
SB-203186 (10-6 M) antagonized the enhanced contractions induced by 5-HT (Fig. 47B). 
The EFS-induced contractions and 5-HT-induced enhancement of contractions were 
prevented by 10-6 M atropine (data not shown).  
 
Effect of 5-HT on electrically stimulated outflow of [3H]ACh from human gastric antral 
preparations. 
  ES (3 Hz, 60 V, 1 msec, for 2 min) evoked the outflow of [3H]ACh over the 
spontaneous [3H]ACh outflow from the mucosa-free preparations of the human gastric 
antrum. The ES-evoked outflow of [3H]ACh was prevented by 3 x 10-7 M TTX (data 
not shown), indicating that the released [3H] originates from the nerve terminals. 
  ES was applied 4 times every 30 min to the same preparation. The ratio of S3-evoked 
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[3H]ACh outflow / S2-evoked [3H]ACh outflow and S4-evoked [3H]ACh outflow / 
S2-evoked [3H]ACh outflow were respectively compared in three preparations from the 
same donor. There were no significant differences in the ratio of S3-evoked [3H]ACh 
outflow / S2-evoked [3H]ACh outflow and S4-evoked [3H]ACh outflow / S2-evoked 
[3H]ACh outflow in the absence of 5-HT.  
5-HT at 10-8 M to 10-5 M potentiated the ES-evoked outflow of [3H]ACh from the 
preparations of human antrum, in a concentration-dependent manner (Fig. 48A). 
SB-203186 (10-6 M) completely antagonized 5-HT (10-6 M)-induced potentiation (Fig. 
48B). 
 
Effect of CJ-033466 on electrically stimulated outflow of [3H]ACh from human gastric 
antral preparations. 
CJ-033466 at 10-9 M to 10-7 M potentiated the ES-evoked outflow of [3H]ACh from 
the preparations of human antrum, in a concentration-dependent manner (Fig. 49A). The 
maximal potentiation by CJ-033466 was reached at a concentration of 10-7 M. 
CJ-033466 at 10-6 M induced weaker potentiation than that observed at 10-7 M. 
SB-203186 (10-6 M) completely antagonized CJ-033466 (10-7 M)-induced potentiation 
(Fig. 49B). 
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 Figure 47. Typical pattern of enhancement of electrical field stimulation
(EFS)-induced contraction by 5-HT at 10-6 M (A) and inhibitory effect of 
SB-203186 (10-6 M) on 5-HT-enhanced contraction (B) in the presence of 
methysergide (10-7 M), ketanserin (10-7 M) and granisetron (10-7 M). - 84 -
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 Figure 48. Concentration-response curves for 5-HT4 receptor-mediated potentiation
of electrically stimulated [3H]ACh outflow (A, n=2) and effect of SB-203186 on the 
5-HT4 receptor-mediated potentiation of electrically stimulated [3H]ACh outflow (B, 
n=3) from the gastric antrum isolated from human.  Electrical stimulation (3 Hz, 1 
msec, 60 V) was applied for 2 min in the presence of methysergide (10-7 M), 
ketanserin (10-7 M) and granisetron (10-7 M). The [3H]ACh outflow was represented 
as a ratio of the release evoked by the third or fourth stimulation (S3 or S4) to that
by the second stimulation (S2). 5-HT was present during the third and fourth 
stimulation (S3, S4). SB-203186 was present during the fourth stimulation (S4). 
Each point represents the mean ± S.E.M.  #: P<0.05, compared with control 
value. *: P<0.05, compared with the value in the absence of SB-203186 (Unpaired
t-test). - 85 -
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 Figure 49. Concentration-response curves for CJ-033466-mediated potentiation of
electrically stimulated [3H]ACh outflow (A, n=2-3) and effect of SB-203186 on the 
CJ-033466-mediated potentiation of electrically stimulated [3H]ACh outflow (B,
n=3) from the gastric antrum isolated from human.  Electrical stimulation (3 Hz, 1 
msec, 60 V) was applied for 2 min in the presence of methysergide (10-7 M), 
ketanserin (10-7 M) and granisetron (10-7 M). The [3H]ACh outflow was represented 
as a ratio of the release evoked by the third or fourth stimulation (S3 or S4) to that
by the second stimulation (S2). CJ-033466 was present during the third and/or fourth
stimulation (S3, S4). SB-203186 was present during the fourth stimulation (S4). 
Each point represents the mean ± S.E.M. *: P<0.05, compared with the value in
the absence of SB-203186 (Unpaired t-test). - 86 -
4. Discussion 
 
  5-HT enhanced EFS-evoked contractions which were antagonized by atropine. The 
responses to 5-HT were obtained in the preparations under the 5-HT1, 5-HT2 and 5-HT3 
receptors blockade. This enhancement was prevented by the 5-HT4 receptor antagonist. 
These results indicate that stimulation of 5-HT4 receptors accelerates the cholinergic 
transmission in the human gastric antrum. 
  Application of ES to the preparations preloaded with [3H]choline evoked the [3H] 
outflow. This [3H] outflow was prevented by TTX. Thus this [3H] outflow may probably 
be the [3H]ACh originates from nerve terminals. 5-HT enhanced ES-evoked [3H]ACh 
outflow which was antagonized by SB-203186 under the application of 5-HT1, 5-HT2 
and 5-HT3 receptor antagonists. Therefore, 5-HT enhanced ES-evoked [3H]ACh outflow 
via stimulation of 5-HT4 receptors. 
  The results obtained in the human gastric antrum were similar to those in the guinea 
pig antrum (116). There is a possibility that the 5-HT4 receptors noted on the myenteric 
plexus in the human gastric antrum by receptor autoradiography (115) are located on the 
cholinergic neurons. Therefore, stimulation of 5-HT4 receptors located on the myenteric 
plexus of human gastric antrum accelerates the ACh release from the cholinergic nerve 
terminals, and may stimulate the motor activity of gastric antrum. The responses to 
5-HT observed in the human gastric antrum are different from the findings in the 
isolated human colonic preparations, in which stimulation of 5-HT4 receptors induced 
relaxations of circular muscles (111). This difference could at least in part be due to the 
location dominantly expressed 5-HT4 receptors in tissue, on neurons or on smooth 
muscles.   
  CJ-033466 enhanced ES-evoked [3H]ACh outflow which was antagonized by 
SB-203186 under the application of 5-HT1, 5-HT2 and 5-HT3 receptor antagonists. 
These results indicate that CJ-033466 enhanced ES-evoked [3H]ACh outflow via 
stimulation of 5-HT4 receptors. Therefore, CJ-033466 stimulates 5-HT4 receptors 
located on the myenteric plexus, and accelerates the ACh release from the cholinergic 
nerve terminals, and may express gastrokinetic effects in the human stomach. 
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Concluding Remarks 
 
  In the present study, CJ-033466 demonstrated gastrokinetic actions in all animal 
models, stimulating canine gastric motility both under fasted and postprandial states, 
accelerating rat gastric emptying and stimulating rat gastric motility via stimulation of 
5-HT4 receptors. Other than CJ-033466, only cisapride demonstrated gastrokinetic 
actions in all animal models. CJ-033466 is 30 times more potent on canine gastric 
motility and it is 3 times less potent on rat gastric emptying than those of cisapride. 
CJ-033466 may not have 5-HT2A and 5-HT2B receptor antagonistic activities which 
cisapride, mosapride and tegaserod have. CJ-033466 also stimulated 5-HT4 receptors 
located on the myenteric plexus of human gastric antrum which may accelerate the ACh 
release from the cholinergic nerve terminals, and may stimulate the motor activity of 
gastric antrum.  
  In rat stomach circular muscle, regional and functional differences of 5-HT receptor 
subtypes has been identified. In the antrum, the contractile responses to 5-HT are 
mediated by 5-HT receptors on both smooth muscle and neurons. 5-HT induces 
contractions via 5-HT2A and 5-HT2B receptors and relaxations via 5-HT4 receptors. In 
the corpus, 5-HT induces contractions via 5-HT2A receptors on smooth muscle. In the 
fundus, the contractile responses to 5-HT are mediated by 5-HT receptors on smooth 
muscle. 5-HT induces contractions via 5-HT2B receptors and relaxations via 5-HT2A and 
5-HT4 receptors. Contractile responses to 5-HT in the rat stomach circular muscle 
present regional and functional differences, which are species-specific. 5-HT induces 
contractions of the circular muscle strips from all three gastric regions. The sensitivity 
to 5-HT of the fundus is higher than those of antrum and corpus. The regional 
differences of the sensitivity to 5-HT may be regulated by several 5-HT receptor 
subtypes which modulate gastric emptying in a cooperative way in rats. 
  CJ-033466 and cisapride demonstrated gastrokinetic actions in all animal models and 
CJ-033466 may stimulate the motor activity of the stomach in human. CJ-033466 could 
fill up the unmet needs after the withdrawal of cisapride from the clinical use.   
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